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ABSTRACT 
 
The prolonged success of cellular encapsulation in delivering insulin to 
treat Type I Diabetes has encouraged researchers to conceptualize ways in 
which cellular encapsulation can be implemented in an array of other clinical 
applications.  This thesis investigated the development of a novel in-house textile 
hollow fiber spinning process in order to encapsulate cells.  After development of 
the cellular encapsulation methods, a 21 day in vitro macroscopic evaluation was 
employed to confirm cellular viability and quantify the metabolic activity response 
of green fluorescent protein (GFP) labeled bovine mammary epithelial cells 
(MAC-Ts) that were either suspended in a low viscosity sodium alginate based 
solution, manually injected into the lumen of the hollow fiber (MI method), and 
later immobilized through a gelation process; or pre-mixed and co-extruded with 
a medium viscosity sodium alginate based solution (CO-X method), and 
immobilized inside the walls of the hollow fiber.  No decrease in fluorescence 
was observed, and it was found that the CO-X and MI methods provided total 
lactic acid productions of 1.6 and 1.5 g/L glucose consumptions of 6.1 and 4.0 
g/L, respectively, after 21 days of culturing.  Histomorphological analyses 
revealed that the average cell area of MAC-Ts increased 25 and 88% after 21 
days of encapsulation under the CO-X and MI methods, respectively.  There was 
little to no evidence of cell clusters, and oval, cobblestone morphologies.  Based 
on our findings, it is concluded that our novel in-house textile hollow fiber 
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spinning process can be used to encapsulate cells using the CO-X and MI 
methods.   
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PREFACE 
 
Cellular encapsulation is a branch of tissue engineering that seeks to 
repair, restore, and maintain normal tissue function by implanting immunoisolated 
cells to deliver therapeutic agents.  The prolonged success of cellular 
encapsulation to deliver insulin in the treatment of Type I Diabetes has 
encouraged researchers to conceptualize ways in which cellular encapsulation 
can be employed in an array of clinical applications.  These efforts include the 
development of cellular encapsulation technologies that can be modified to meet 
the requirements posed by specific applications.   
It is our contention is that we can encapsulate cells in a 3D-matrix by 
using an in-house novel textile hollow fiber spinning process.  This thesis 
investigates our hypothesis in three parts.  The first part of the study 
characterizes key properties of sodium alginate, our initial encapsulation material 
of choice.  The second part of the study involves the development of two cellular 
encapsulation methods, one in which green fluorescent protein (GFP) labeled 
bovine mammary epithelial cells (MAC-Ts) are co-extruded (CO-X) with the 
sodium alginate.  The second encapsulation method involved manually injecting 
(MI) an alginate-based cell suspension into the lumen of a pre-fabricated hollow 
fiber.  The third part of the study is an in vitro 21 day macroscopic evaluation of 
the cellular response to these two encapsulation methods in which the cell 
 xvi
viability was confirmed, the cell respiration was quantified, and the cell 
morphology was characterized.   
 
CHAPTER ONE 
 
INTRODUCTION 
 
 
1.1 Rationale for tissue engineering 
According to the United States Department of Health and Human 
Services, nearly 27,000 organs were transplanted in the year 2004, which was 
an 11% increase from the previous year.  However, despite the increase in 
transplantations, there were more than 87,000 patients waiting to receive organ 
transplants in the year 20041. Although new health technologies have been 
developed, the need for replacement of living tissues and organs from donors 
remains.  Tissue engineering is a field that has the potential to yield readily 
available functioning organs.  The goal of tissue engineering is to decrease the 
number of needed transplants by repairing, improving and maintaining damaged 
tissues through the development of biologically based devices.   
1.2 Rationale for cellular encapsulation 
One tissue engineering application is the repair of diseased tissue through 
the delivery of drugs from encapsulated living cells.  Cellular encapsulation 
describes the capture of living cells in a suitable immunoprotective capsule.  The 
capsule allows the diffusion of oxygen and nutrients to the cells and the secretion 
of wastes and therapeutic drugs produced by the cells into the body across a 
highly selective membrane.  Ideally, the membrane prevents the intrusion of cells 
and cytokines or regulatory proteins that induce apoptosis (programmed cell 
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death) of cells within the encapsulated environment.  Thus, cellular encapsulation 
allows the transplantation of cells without the adverse long-term effects of using 
immunosuppressant drugs. In order to achieve high selectivity, the membrane’s 
thickness, pore size, and surface chemistry must be well controlled.   
1.3 Previous applications of cellular encapsulation 
The literature mentions a number of diseases that have been treated 
using cellular encapsulation.  These ailments include anemia and hemophilia2, 
chronic pain3-5 and Parkinson’s disease6-8, pituitary and central nervous system 
insufficiencies5,9, liver failure10-18, and Type 1 diabetes19,20. 
Extensive research has been conducted on the encapsulation of 
pancreatic islets for treating insulin dependent (Type 1) diabetes, after 
transplanted pancreatic islets successfully delivered insulin in 
immunosuppressed patients21.  Thus, cellular encapsulation was initiated to 
circumvent the need for immunosuppressants.  Studies with diabetic primates in 
which porcine (pig) islets were encapsulated also suggest the potential of the 
technology22.  Despite promising results in small and large animal models23; 
however, human trials that have attempted to establish prolonged 
normoglycemia have had limited success.  Only 11% of all allotransplants 
performed before 1993 in diabetes mellitus patients resulted in normoglycemia 
and insulin independence post surgery6.  The limited success in these clinical 
trials is attributed to: variability in the encapsulation processes that expose cells 
to the host rejection and promote enhanced scar tissue formation around the 
encapsulation device6,7; low islet seeding densities2; and restricted waste 
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transport out of the encapsulation device due to strict pore size limitations2.  
Soon-Shiong and coworkers have been able to address these variabilities by 
improving the encapsulation process to allow higher islet seeding densities under 
relatively low doses of immunosuppressants24,25.  Other researchers have 
suggested that cell viability can be enhanced by implanting the encapsulation 
device months prior to adding cells26.  The cell viability is enhanced because at 
the time of cell transplantation, the exchange across the membrane of the 
encapsulation device has increased. 
1.4 Potential uses of cellular encapsulation 
One of the main goals of tissue engineering is to provide cellular devices 
and synthetic components that restore, maintain, or improve tissue function. 
Specifically, tissue engineers seek to better understand drug delivery, 
biocompatibility, and cell function in order to improve the success rate of medical 
devices.  The human body naturally responds to an implanted device (or “foreign 
body”) by surrounding the implant with cells that will form a collagen capsule 
around the matrix over time.  The transfer of vital nutrients to implanted living 
tissue and the movement of mechanical components can be prohibited by the 
deposition of a thick, fibrous capsule around an implant.   
Over 13 million textile medical devices that are implanted annually in the 
United States are affected by this naturally-occurring process.  These implants 
range from simple fixation devices and lens implants to more complex devices 
such as ear vent tubes and artificial heart valves10.  
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Although these devices have improved the quality of life for patients, they 
often do not emulate the multitude of dynamic biologic and reparative processes 
that occur in normal tissue.  Accordingly, the demand for medical devices with 
bioactive surfaces must be met with materials whose compatibility is tuned to a 
particular medical application.  Cellular encapsulation may be useful in tuning 
textile based devices such as arterial or skin grafts, where the constituent fibers 
serve as the drug delivery vehicles.   
1.4.1 Arterial grafts 
Tissue is categorized as either soft or hard; replacement tissue must 
maintain the appropriate structural and mechanical properties in order to remain 
functional within the body.  One specific type of soft tissue implant is the arterial 
graft.  In 2005, the potential annual market for small-diameter arterial graft 
market was estimated to be more than $1.5 billion27.  One of the major problems 
with transplanting human arterial homografts is their rapid degeneration, leading 
to decreased patency of the grafts.  Tran and coworkers chemically stabilized 
autologous saphenous vein segments to enhance graft stability28; however, since 
the saphenous vein has a small wall thickness, it is limited in application to 
coronary artery bypass.   
To avoid these complications as well as donor site morbidity issues, 
surgeons have attempted to use grafts constructed from synthetic and natural 
textile materials as to develop vascular conduits.  The most prominent examples 
of early surgical use of synthetic textile materials to replace damaged vasculature 
were the implantation of an artificial heart valve comprised of a methyl 
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methacrylate shell and silicone-coated hollow nylon poppet by Hufnagel29,30 and 
the clinical application of Vinyon N in the form of an arterial graft by Blakemore 
and Vorhees9,30,31.  Although the Vinyon N graft developed septums or partitions 
within the graft, the possibility of developing artificial systems was realized.  
Thus, one of the first key initiatives of tissue engineering was to improve vessel 
patency by providing a more biocompatible interface between the graft material 
and the host by enlarging the selection of compatible medical materials and the 
incorporation of autologous endothelial cells onto these polymeric scaffolds.  
Polyurethane (PU) prostheses have been shown to be instable after long-
term use because of patency issues32.  The main material in use for arterial 
grafts is expanded polytetrafluoroethylene (ePTFE).  Comparatively, ePTFE 
grafts are more costly to manufacture, difficult to attach, and do not provide an 
appropriate interface with the body that allow cellular infiltration.  Another 
commonly used material type is polyethylene terepthalate, which includes 
polyester or Dacron.  Woven Dacron fabrics have been found to prevent liquid 
leakage, and their high modulus and low wear resistance make them easier to 
sew in place and handle.  Knitted Dacron prostheses however, are flexible and 
porous, which allow the body tissue to grow inside the graft to form a distinctive 
intima-like layer.  Surgeons have been able to prevent blood leaks in the knitted 
Dacron prostheses by allowing the patient’s blood to clot on the graft’s outer 
surface21.  However, using blood clots to seal these prostheses is associated 
with increased blockage downstream of the graft.  To avoid these additional 
complications, pre-existing knitted Dacron grafts have been sealed by 
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incorporating PU with functionalized carboxyl groups that allow covalent protein 
bonding33.  Also, sealed hybrid grafts containing both a synthetic and biological 
component have been manufactured.  Biological components, such as collagen, 
albumin, and gelatin, have been used to fill surface voids on the prostheses to 
prevent the initial bleeding of the grafts21.  By preventing grafts from leakage, 
hybrid grafts are beneficial because they decrease the need of blood 
replacement during surgery.  As the tissue surrounding the grafts grows and 
infiltrates the scaffold, these biological components simultaneously disappear 
and allow tissue ingrowth to occur.  Therefore, an effective hybrid prosthesis 
would be one with an appropriate interface in which the disappearing rate of its 
biological component is highly predictable. 
1.4.2 Skin grafts 
 Another soft tissue application in which tissue engineering technology has 
been used to meet increased harvesting demands is skin replacement.  The 
largest drawback to the traditional use of autologous skin is donor site morbidity.  
Although allografts harvested from cadavers have been used, graft rejection 
persists.  Even more peculiar are the materials that can be used as skin wound 
dressings.  Typically, skin grafts are used to expedite the healing process of burn 
victims.  They may diminish the need for foot amputations and may serve as a 
remedy to the chronic foot ulcers of many diabetic patients.  These topical grafts 
must be pliable, antimicrobial, and selectively permeable to exudate or wound 
discharge without allowing the loss of fluids and electrolytes from the wound34.  
The surface characteristics of skin grafts should be such that the graft peels 
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away from the wound easily, without disrupting the growth of the underlying new 
skin.  For these reasons, few materials meet the performance criteria that are 
desired for skin grafts.  Amongst the possible candidates are absorbable or 
degradable polymers which include a combination of collagen, chitin, 
polyglycolide (PGA) and poly-L-lactide (PLL)35, or extracellular matrices (ECM) 
such as hyaluronic acid36 that encourage tissue ingrowth.  These materials can 
incorporate fibroblasts (dermal cells) and keratinocytes (epidermal cells) into 
porous sheets or woven fabrics known as split-thickness grafts.  The first 
commercially available living skin equivalent was Apligraf®, which features a 
bovine collagen dermis seeded with allogeneic fibroblasts and keratinocytes37. 
Along with Apligraf®, the uses, advantages and disadvantages of numerous other 
commercially available skin grafts are shown below in Table 1. 
Kirsner suggested, in 1993, that autologous skin grafts can not only 
replace tissue, but also provide stimulating growth factors to promote tissue 
growth38.  Also of note was the observation that increasing the time to wound 
closure changes the biochemistry of the wound and increases the likelihood of 
scar formation39.  More recent clinical trials substantiate similar pharmacological 
effects in skin grafts that incorporate allogeneic or donor cells40.  Because the 
autologous cell retrieval, cell population, and graft preparation process may 
extend from three to five weeks, thereby increasing a patient’s susceptibility to 
infection41, novel approaches to decrease culturing time are being investigated42.  
Despite the new developments in skin graft technology, there have been few to 
no reports of the currently available skin grafts promoting new tissue growth 
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without the formation of scars in severe burn victims.  Therefore, an opportunity 
exists for the development of a cost-effective skin graft that promotes scarless 
wound healing and reduced inflammation with comparable re-epithelization times 
to existing commercial grafts. 
Table 1: Alphabetical listing of commercial skin substitutes, adapted from Eisenbud et al.43  
Product Company 
FDA-Approved 
Indications (PMA, HDE, 
510K, or other)* 
Other Published Uses Competitive Advantages Disadvantages 
Alloderm® LifeCell Inc. Burns/full-thickness wounds (allograft) 
Other formulations 
(CymetraTM, RepliformTM) 
used to fill soft tissue defects 
in plastic, gynecological, 
dental and urologic surgery 
Not rejected; no cases of viral 
transmission after >100,000 
product applications; 2 year 
shelf life 
Lacks cellular components 
Apligraf® Organogenesis Inc. 
Venous/diabetic ulcers 
(PMA) 
Epidermolysis bullosa; 
anecdotal reports, case studies 
and pilot trials in many other 
skin conditions 
Mimics function of dermis; 
cryopreserved product 
5 day shelf life; awkward 
logistics of ordering and use 
Biobrane®, 
Biobrane-L® 
Bertek 
Pharmaceuticals 
Partial-thickness 
burns/meshed 
autografts/donor sites 
(510K) 
 
Three year shelf life; good 
barrier function and water 
exchange 
No antimicrobial 
properties/temporary 
replacement requires 
removal in 7-10 days 
CeladermTM Celadon Science LLC (None) 
Partial and full thickness 
burns, venous wounds 
>6 month shelf life; relatively 
inexpensive; good results in 
many pilot studies 
Not FDA approved 
Dermagraft® Smith & Nephew Inc. 
Diabetic foot ulcers 
(PMA); ulcers secondary 
to epidermolysis bullosa 
(HDE) 
 Mimics function of dermis; cryopreserved product 
Difficult logistics of ordering 
and application; short shelf 
life (unless stored 
cryopreserved) 
Epicel® Genzyme Biosurgery 
Deep partial-thickness and 
full-thickness burns 
(HDE); congenital nevi 
(HDE) 
 
Autologous cells; no rejection, 
high incidence of permanent 
take 
Fragile; custom preparation; 
one day shelf life; inferior 
cosmesis in many patients 
 
*PMA, pre-market approval; HDE, humanitarian device exemption; 510K substantial equivalence to predicate (previously approved) device 
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Product Company FDA-Approved Indications (PMA, HDE, 510K, or other)* Other Published Uses Competitive Advantages Disadvantages 
EZ 
DermTM 
Brennen Medical 
Inc. 
 
Partial-thickness burns/venous, diabetic, 
pressure ulcers; porcine xenograft (510K) 
 Relatively long shelf life 
 
Potential immune response 
and/or disease transmission 
Integra® 
Integra 
LifeSciences 
Corp. 
Deep partial-thickness and full-
thickness burns (PMA)  
Two layers; good barrier 
function; used in over 10,000 
patients; moderate shelf life 
Operative removal of 
silicone layer and 
autograft required 
Laserskin® Fidia Advanced Biopolymers (None) 
Partial thickness burns, 
chronic venous, pressure 
ulcers, vitiligo 
Autologous cells; no rejection; 
high incidence of permanent 
take 
Two day shelf life; custom 
preparation; fragile 
Oasis® Healthpoint 
Partial/full-thickness pressure, venous 
and diabetic wounds/partial-thickness 
burns (510K) 
 1.5 year shelf life Potential immune response
OrCel® Ortec International Inc. 
Split-thickness donor sites (PMA); 
mitten hand deformity surgery of 
epidermolysis bullosa (HDE) 
Venous and diabetic 
wounds 
Mimics cytokine expression of 
healing skin; 9 month shelf life 
cryopreserved 
Requires cryopreserved 
storage 
TransCyte® Smith & Nephew Inc. 
Full- and partial-thickness burns 
(PMA)  1.5 year shelf life frozen 
Silicone membrane must 
be removed 
Table 1 (Continued): Alphabetical listing of commercial skin substitutes, adapted from Eisenbud et al.43 
 
*PMA, pre-market approval; HDE, humanitarian device exemption; 510K substantial equivalence to predicate (previously approved) device 
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1.5. Controlling the inflammatory response through cellular encapsulation 
In order to formulate new materials that incorporate cells that deliver 
growth factors, one must address the role of the inflammatory response in wound 
healing.  Based on correlations developed between porosity, material surface 
chemistry and host response of thirty-seven types of synthetic vascular grafts, 
Wesolowski concluded that the inflammatory response is controlled by material 
chemistry and other material factors that can stimulate biochemical changes in 
necrotic scar tissue44.  Today, it is known that in regulating wound healing, it is 
necessary to control the molecules produced by activated macrophages.  
Namely, activated macrophages secrete matrix metalloproteases which degrade 
the surrounding collagenous tissue and release chemokines that promote the 
migration of fibroblasts from the adventitia layer of the surrounding blood vessels 
to secrete a new matrix of fibronectin and collagen45.  Depending upon the 
composition and condition of the existing tissue, these new constituents will form 
acellular, nonfunctional fibrotic granular tissue, or scar tissue, that will isolate the 
implant from the physiological environment.   
1.5.1 Preventing the activation of macrophages 
Therefore, it is important to address the molecules that are known to have 
a key role in activating macrophages.  These molecules do not act alone, but as 
part of an intricate system of synergistic pairs.  Amongst these factors are 
interferon gamma (IFN-γ), tumor necrosis factor alpha and beta (TNF-α and TNF-
β), interleukin 10 (IL-10), IL-4, and transforming growth factor beta (TGF-β).  IFN-
γ and TNF-β are lymphokines that are predominantly produced by IL-12 
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stimulated Th-1 type T cells.  These lymphokines encourage macrophages to 
release nitrous oxide and other toxins that kill and degrade bacteria and other 
foreign material they have engulfed.  The TNF-α molecule acts as the 
macrophages’ signaling device, upregulating the inflammatory response by 
recruiting, activating, and promoting the maturation of inflammatory cells.  IL-4 
and IL-10 both inhibit macrophage production of cytokines by suppressing the 
formation of Th-1 type T cells46.  
ACCESSORY 
FUNCTION
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FUNCTION
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FUNCTION
INFLAMMATORY 
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Figure 1.1: The role of macrophages in inflammatory responses. During an 
inflammatory response, macrophages can display both inflammatory and anti-
inflammatory functions.  Through the regulation of transforming growth factor 
beta (TGF- β), however, macrophages can be induced to inhibit their effector 
functions, allowing for a more directed wound healing response47.  
 
Of particular interest is TGF-β because it can be used to control the 
inflammatory cytokine production from macrophages47.  Also, the ratios and 
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regulation of its isoforms have been shown to play key roles in promoting 
scarless wound healing48-50.  In mammals, TGF-β (25kDa) exists in three unique 
homodimers (TGFβ1-3)51.  It is important to note that these isoforms not only 
differ in conformation, but also in their potency and functionality.  TGF-β1 and 
TGF-β2 are derived from platelets and macrophages, whereas the primary cell 
source of TGF-β3 is fibroblasts52. These factors function as chemotactic agents 
to recruit inflammatory cells and fibroblasts.  Although inappropriate amounts of 
these growth factors promote the deposition of fibrous epithelial layers in 
diseases such as glomerulonephritis and proliferative vitreoretinopathy50, their 
proper regulation has an unlimited arena for therapeutic use.  The introduction of 
exogenous TGF-β3 at cutaneous wound sites in rats has been shown to prevent 
scarring in cutaneous wounds50.  Prevention occurs by decreasing the wounded 
tissue density of macrophages and monocytes, increasing blood vessel density 
in the healing wound, and decreasing the deposition of fibronectin and collagen 
Types I and III by fibroblasts.  Respectively, these events promote healing in 
which there is a less severe inflammatory response, less likelihood for infection 
and necrosis, and a less contracted and a more organized skin architecture.  
Moulin and coworkers’ in vitro studies suggest that the addition of TGF- β3 (most 
potent) decreases the contraction of adult wounds by increasing the expression 
of α-smooth muscle (SM) actin and the α3 and β1 integrin subsets of fibroblasts, 
while not affecting the fibroblasts’ growth or contractile capacity and their 
expression of α1 and α2 integrin subsets.  However, the studies suggest that in 
fetal fibroblasts, in which wounds heal without contractions and scars, the 
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addition of TGF- β3 would inhibit cellular growth and contractile capacity and 
decrease the expression of α1, α2 and β1 integrin subsets, while not affecting the 
expression of α-SM actin and the α3 integrin subset49.  Collectively, the 
differences in the ratios of TGF- β isoforms that are present during wound 
healing and the intrinsic cellular responses to TGF- β may account for the 
differences in healing quality between fetal and adult wounds. 
1.5.2 The role of endothelial cells in wound healing 
Although macrophages are responsible for secondary phases of 
inflammation and fibroblasts are responsible for extracellular matrix deposition, 
endothelial cells play a major role in inflammation resolution53.  Endothelial cells 
secrete soluble factors that promote wound closure and neovascularization.  
Neovascularization is promoted by the activation of quiescent endothelial cells by 
angiogenic factors such as VEGF, bFGF, IL-8, PDGF, and hematopoeietic 
growth factors derived from tumors or inflammatory cells.  Activated endothelial 
cells cause basement membrane proteolysis and endothelial cell proliferation, 
migration, and alignment to form rope-like structures, followed by vessel 
maturation54,55.  Implanting autologous tissue causes donor site morbidity.  
Implanting allogeneic and xenogeneic cells into the body causes an immune 
response that may result in lysis of implanted cells.  However, if these cells were 
placed into an immunoprotective, semi-permeable cocoon that allowed nutrients 
and waste transport, but denied host’s antibodies, this type of implantation might 
be successful.  Ideally, one would expect the endothelial cells to be activated by 
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the appropriate factors and to begin directing wound healing from their location 
inside the encapsulation device. 
The incorporation of endothelial cells into small diameter artificial arterial 
grafts will promote the regulation of thrombotic activity in the lining of natural 
blood vessels56.  It has been proposed that surrounding endothelial cells with 
porous, hollow fiber components might allow allogeneic or xenogeneic 
transplantation with minimal immune response.  These hollow fibers would be 
constructed in either woven or nonwoven forms to create a bioactive surface for 
medical devices and soft tissue transplants or to introduce a clinically applicable 
arterial substitute.  The novel bioactive surface would incorporate genetically 
modified endothelial cells that would direct wound healing at the implant site by 
delivering healing agents such as TGF-β3.  The use of these devices as arterial 
grafts and living skin replacements would promote specific and complete wound 
healing, which would increase the functionality of new tissues and improve the 
patient’s outcome. 
1.6 Alginate: a classic encapsulation material 
Material selection of the immunoisolation membrane has enormous 
influence on the success of cellular encapsulation devices.  Prakash and Soe-Lin 
have reviewed the strengths and weaknesses of various materials used to 
encapsulate living cells57.  The biomaterials reviewed include alginate and 
alginate variants.  Alginates are linear unbranched polymers (carbohydrates) that 
are found in various sources of brown seaweed and which contain randomly 
arranged blocks of α-(1?4)-linked D-mannuronic acid (M) and α-(1?4)-linked L-
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guluronic acid (G) residues of high molecular weight (Figure 1.2)58.  Although the 
M and G blocks are epimers and are chiral at the C4 carbon, the conformation of 
the G block allows its carboxylic acid groups to be more readily available for 
prosthetic modification and crosslinking by positive divalent metal ions such as 
calcium.   
 α-(1→4)-linked L-guluronic acid (G)
 
 
β-(1→4)-linked D-mannuronic acid 
Figure 1.2:  A common GGMM block found in alginate.  
The degradation of alginate can occur in calcium alginate when the 
calcium diffuses into a lesser concentrated physiological environment.  
Degradation of alginate can be retarded through the esterification of carboxylic 
acids groups on the G blocks57.  Alginate and alginate variants are promising 
polymers for live cell encapsulation because they can provide short/medium-term 
mechanical stability, flexible permselectivity, and low immunogenicity.   
1.6.1 Apparent viscosity of sodium alginate 
Viscosity is the limiting factor in determining sodium alginate concentration 
and spinnability, as well as the membrane’s immunoprotective permeability and 
the diffusion capability.  Moreover, cell viability is highly dependent upon 
maintaining low alginate viscosity.  Kong and coworkers demonstrated that 
mixing suspended osteoblasts in a highly viscous sodium alginate matrix resulted 
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in a substantial loss of cell viability59; however, use of low molecular weight 
alginates increased the brittleness of the hydrogels.  The prescribed method of 
circumventing or minimizing these issues is to combine low molecular weight 
alginates with a small fraction of high molecular weight alginates60. 
1.6.2 M/G ratio of alginates 
M/G ratio is an important characteristic in the design of an alginate 
encapsulation device.  The %G in the alginate hydrogel determines the rigidity of 
the gel.  Mooney and colleagues suggest that a higher %G promotes cell 
proliferation whereas a lower %G causes cells to differentiate61.  Since cells are 
more likely to adhere to and proliferate on more rigid gels, the %G not only 
influences gel rigidity, but also influences cell function by guiding cell-matrix 
interactions.  Kong and coworkers showed that irradiation methods can decrease 
the viscosity of the sodium alginate matrix without affecting the % G content or 
the gelling capability of the gel59. 
1.6.3 Sterilization of alginates 
It was once theorized that the high M content of some alginates induced 
an immune response.  However, recent data suggest that contaminants are the 
more likely cause of the response, and novel purification methods have been 
developed that render alginates of various contents eligible for implantation62.  
Other techniques have been suggested for sterilization, including sonochemical 
and ultraviolet light methods63.  Autoclave sterilization of alginate also effectively 
decreases the molecular weight by polymer chain degradation64,65. 
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1.6.4 Importance of alginate processing parameters 
The potential use of alginate in cellular encapsulation applications is 
determined by the processing parameters used to construct a specific form. 
Research conducted by Burg and coworkers indicated that porous calcium 
alginate beads facilitated cell adhesion when compared with other specific 
alginate forms such as nonporous beads, tubes, and solid masses66 
(Table 1.2).  Porous calcium alginate beads are indeed noteworthy for their high 
surface to volume ratio.    
Table 1.2: The influence of alginate processing parameters on cell viability /   
tissue ingrowth 
 
1.6.5 Incorporation of cells into alginate 
The technology of fabricating hollow fiber membranes for filtering 
applications already exists67,68 and might readily be transferred to process 
alginate.  Clinically, islet cells have been incorporated into poly (acrylonitrile-co-
vinyl chloride) hollow fibers by Lacy and coworkers2.  Emerich and colleagues 
compared the delivery of dopamine from cells encapsulated into the lumen and 
wall of polyacrylonitrile-vinyl chloride copolymer (PAN/PVC) hollow fiber 
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membranes69.  Li suggests that suspending cells in a 1% alginate hydrogel 
matrix for cells prevents necrotic cluster formation caused by cell – cell 
adhesion70. 
1.6.6 Pore diameter 
The importance of pore diameter throughout the alginate hydrogel fibers 
arises due to the target biological application.  Too large a pore diameter may 
allow the influx of complements that could mark the cells within the alginate 
matrix as foreign, causing the activation of an immune response.  If the pore 
diameter is too small, then there could be a delay or burst effect of the healing 
agents released from the cells.  
Pore introduction techniques have been reviewed that will allow proper 
diffusion of nutrients and oxygen without initiating an immune response in the 
alginate hollow fiber matrix.  Mooney and collegues have shown that pores can 
be incorporated into poly-lactide-co-glycolide scaffolds through a gas foaming 
technique without the use of organic solvents71; however, this technique is limited 
to semi-crystalline polymers and does not lend well to hydrogels.  Lyophilization72 
and swelling techniques54 have also been evaluated and allow more widespread 
treatments of materials; however, both methods are applied post processing.   
1.7 Project goals 
 Given the potential clinical benefit of producing a cellular alginate with 
permselectivity using minimal processing steps, the goal of this research was to 
demonstrate cellular encapsulation in hollow alginate fibers using two innovative 
spinning methodologies and a newly designed benchtop fiber spinning 
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apparatus.  Long-term, this technology could lead to the development of cellular 
fiber based products that include biosynthetic skin grafts and arterial graft 
replacements.   
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CHAPTER TWO 
 
MATERIALS AND METHODS 
 
 
2.1 Investigative approach 
 
Our approach to achieving optimized cellular encapsulation in the long 
term includes four crucial topics, as shown in Figure 2.1.  In order to first 
demonstrate that this spinning technology can be used to encapsulate cells, 
Topics I and IV will be discussed extensively within this thesis, while Topics II 
and III remain topics of future interest and investigation.   
 
Figure 2.1: Venn diagram displaying the research topics required to optimize 
cellular encapsulation includes evaluating the effects of the solution properties of 
alginate (Topic I), fiber spinning parameters (Topic II), and hollow fiber 
morphology and material (construct) properties (Topic III) on cell viability (Topic 
IV).    
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In Topic 1, we characterize the solution properties of several types of 
alginate in order to determine which alginate type is best for spinning fibers and 
incorporating cells.  These alginate solution properties have been characterized 
previously in the literature; and, although the equipment used in the literature is 
not readily available in our lab, our contention is that we have successfully 
developed comparable characterization methods that yielded the selection of an 
alginate type with which we pursued further encapsulation studies.  
In Topic 4, we investigate the hypothesis that our spinning apparatus can 
be used to incorporate green fluorescent protein labeled, bovine mammary 
epithelial cells (MAC-Ts) into the walls and lumen of our hollow fibers, and we 
demonstrate that the MAC-Ts remain viable throughout the hollow fibers during 
our 21 day in vitro study.   
2.2 Solution properties of sodium alginate 
2.2.1 Rheological properties of alginate 
 
100 mL solutions of sodium alginate were prepared at concentrations from 
0 – 8 wt% (wt alginate/wt H2O), at increments of 1% by using an overhead stirrer 
(Eurostar digital, IKA®-WERKE, Wilmington, NC).  The distilled water was stirred 
as the alginate powder was dispersed into the water to prevent clumping. 
2.2.2 The effect of alginate concentration on apparent viscosity 
The viscosity behavior of low and medium viscosity (LV and MV) grade 
sodium alginate (Sigma-Aldrich, St. Louis, Missouri) and Acros Organics (AO) 
sodium alginate (Acros Organics, Geel, Belgium) was investigated using a plate 
and cone rheometer (Physica MCR 300 Rheometer; Anton Paar Physica Co., 
Graz, Austria).  Volumes in the amount of 2 mL of the sodium alginate samples 
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were pipetted onto the test plate, which allowed the surface of the disk to touch 
the surface of the sample.  The rheometer applied torque to the cone (PP-25: 
diameter = 24.96 mm and contact angle = 1°; Anton Paar Physica Co., Graz, 
Austria) to achieve the specified shear rates. The US200® software (Anton Paar 
Physica Co., Graz, Austria) automatically calculated the viscosity by multiplying 
the shear stress times the shear rate.  The cone height was adjusted 
appropriately from 1 to 1.5 mm to obtained accurate measurements prior to each 
viscosity measurement, as the height of the bubble was dependent upon 
concentration.  The temperature of the measuring plate was maintained at 25°C 
using the water pump connected to the rheometer.  A constant shear rate (CSR) 
test was used to measure the viscosity profile of these alginates at a shear rates 
up to 100 s-1.   
Additionally, 100 mL solutions of AO alginate were made at 0 – 2 wt%, at 
0.5 wt% increments to provide additional technical knowledge about the 
response of the alginate to changing shear rates (i.e flow rates through the 
syringe) when making alginate beads.  To determine this viscosity profile, a CSR 
test was used to measure the viscosity profile of these alginates at a shear rates 
up to 100 s-1.  The cone type, test sample volume, cone height, and test 
temperature stated for the 2-8 wt% concentrations were held constant throughout 
this study. 
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2.2.3 The effect of autoclaving and adding Dulbecco’s Modified Eagle’s                    
Medium (DMEM) on apparent viscosity 
 
To determine an optimal viscosity for spinning cellular fibers using the co-
extrusion process, it was necessary to determine how the viscosity of alginate 
changes after each processing step.  The alginate is prepared, sterilized, cooled 
to room temperature, and then an additive is mixed with the alginate.  For this 
study, the additive was DMEM, whereas future studies could include biomaterials 
such as gelatin, fibrin or chitosan.  
A 500 mL solution of 6 wt% medium viscosity grade (MV) alginate was 
prepared using an overhead stirrer (Eurostar digital, IKA®-WERKE, Wilmington, 
NC).  To prevent aggregation, the appropriate amount of distilled water was 
stirred in a 1 L glass beaker as the alginate powder was dispersed into the water. 
After 30 minutes of mixing at a shear rate of 2000 min-1, an intermediate sample, 
sample A, was gathered by pouring 20 mL of the alginate into a 100 mL plastic 
specimen cup.    Aluminum foil was loosely placed over the beaker.  The beaker 
was secured in an autoclave oven (Model 3870M; Brinkmann Instruments, Inc., 
Westbury, New York), where it was heated to 121°C using a 45 - minute cycle for 
liquids.  After autoclaving, the beaker was placed in a -20°C freezer for 1 hour of 
cooling.  A 20 mL sample of the cooled alginate was pipetted into a 100 mL 
specimen cup and labeled as sample B. Cooled alginate in aliquots of 10 mL was 
pipetted into each of two 100 mL plastic specimen cups, samples C and D, using 
a sterilized 10 mL pipette and electric pipetter. 1 mL of DMEM was pipetted into 
the cup containing sample C, and 10 mL of DMEM were pipetted into the cup 
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containing sample D.  A spoon was used to thoroughly mix the contents of each 
cup.   
Using a plate and cone rheometer, the apparent viscosity of the samples 
A-D was evaluated using a constant shear rate (CSR) test at a shear rate of   
100 s-1 for 60 seconds.  The cone height was 0.5 mm and the measuring plate 
was held at a constant temperature of 22.5°C, the average co-extrusion spinning 
temperature.  The apparent viscosities of samples A-C were related and used to 
predict the intermediate behavior of the spinning solution during preparation.  
2.2.4 Determination of molecular weight 
 
Solutions of low (LV) and medium (MV)viscosity grade sodium alginate 
(Sigma Aldrich, St. Louis, Missouri) and Acros Organics (AO) sodium alginate 
(Acros Organics, Morris Plains, New Jersey) were prepared at concentrations of 
0 – 2 % (wt/vol) at increments of 0.5 %.  A 0.1M sodium chloride solution was 
used as the solvent to minimize molecular coiling.  A rheometer (MCR 300; 
Anton-Paar, Ashland, Virginia) was used to measure the “apparent” viscosity of 
these alginate solutions from shear rates of 0.1 to 100 s-1.  The apparent 
viscosity is highly dependent upon concentration of alginate and shear rate.  The 
relative viscosity of each alginate concentration was calculated by dividing the 
apparent viscosities measured for the solutions by the apparent viscosity of the 
solvent.  The relative viscosity shows changes in viscosity on a solvent basis.  A 
plot was made of the inherent viscosity versus concentration using Microsoft 
Excel®, as shown in Figure 3.1.  It was from these plots that an intrinsic viscosity 
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was interpolated.  A Mark-Houwink plot was then used to correlate the intrinsic 
viscosity and molecular weight, according to methods found in the literature1,2.   
A box and whisker plot was made by using Microsoft Excel© (Microsoft 
Corporation, Redmond, Washington)3-5.  In addition to the plot, the coefficient of 
variation (Cv) and the interquartile mean (IQM) were calculated to determine the 
degree of dispersion for the viscosity average molecular weight results6.  Cv is 
the ratio of the standard deviation to the mean.  Since the IQM excludes the 
lowest and highest 25% of the values in a given data set, it is insensitive to 
outliers and typically preferred over the arithmetic mean or average in measuring 
the data set’s central tendency.  Therefore, the IQM is a more precise calculation 
of the molecular weight. 
2.2.5 Evaluating the M/G ratio of sodium alginate 
A total of three methods were used to calculate the G block percentage of 
each alginate type.  Methods 1 and 2 involved calculating P/T ratios from CD 
spectra. Method 1 used an empirical equation (Eq. 2.1) to estimate the M/G block 
ratio, and a second equation (Eq. 2.2) to calculate the G block percentage 
contained in each alginate type.  Method 2 applied the P/T ratios determined 
from the CD spectra to a correlation chart to estimate the M/G block ratio (Figure 
3.6), and an equation (Eq. 2.3) was fitted to the linear portion of the correlation 
graph to calculate the G block percentage.  The M/G ratio was back calculated 
by using an additional equation (Eq. 2.4).  Method 3 did not involve the use of CD 
spectra but instead equated the M/G block ratio to the ratio of the normalized 
characteristic absorbance peaks at 1028 and 1100 cm-1, that were observed by 
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using Fourier Transform Infrared, Attenuated Total Reflectance (FTIR-ATR) 
spectroscopy (Figure 3.7).   
The following equations were employed to determine the %G block:  
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Eq. 2.6  (Same as Eq. 2 from Method 1) 
 
2.2.5.1 Circular Dichroism (CD) spectroscopy 
Low viscosity (LV) and medium viscosity (MV) alginate (Sigma-Aldrich, St. 
Louis, Missouri) and Acros Organics (Acros-Organics; Fairlawn, New Jersey) 
alginate samples were prepared at 0.04% (weight of alginate/volume of distilled 
water).  The alginate sodium salt granules were dissolved and thoroughly mixed 
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for 5 hours on a magnetic stir plate (Stirrer/Hot Plate; Corning, Corning, New 
York).   
A standard rectangular measurement cuvette with a 20.00 mm pathlength 
(QS -20.00 mm; Starna Cells. Inc., Atascadero, California) was thoroughly rinsed 
with distilled water, dried, and filled to the measurement line with 3.5 mL of the 
prepared solutions.  The cuvette was placed in the cuvette chamber of the 
circular dichroism spectrophotometer (J-810 Circular Dichroism System; JASCO, 
Easton, Maryland).  The three alginate types were analyzed at scanning speeds 
of 20 nm/min and 100 nm/min from 250 nm to 195 nm (the spectrophotometer 
initiates at higher wavelengths and terminates at lower wavelengths).  The data 
was exported from the Spectra Analysis® software to a Microsoft® Office Excel 
2003 (Microsoft Corporation, Redmond, Washington) spreadsheet.  The M/G 
block ratio was calculated as a ratio of the resulting height of the peak (P) to that 
of the trough depth (T), as shown below in Figure 2.2.  The percentage of 
guluronic acid block (%G) was determined through a chart found in the literature7 
that correlated P/T ratios to %G ratios for common sources of alginates.  
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Figure 2.2: Typical CD spectra for Macrocystis pyrifera sodium alginate8.   
 
2.2.5.2 Fourier Transform Infrared Attenuated Total Reflectance  
             (FTIR-ATR) spectroscopy 
 
The FTIR-ATR technique has been used to analysis the chemical 
composition of polymers that are used in a wide variety of applications.  ATR 
works by passing infrared radiation through an ATR crystal.  The ATR crystal has 
a totally reflective surface and refines the infrared radiation into an evanescent 
wave of energy.  When a sample is brought in contact with the surface of the 
ATR crystal, the wave attenuates in regions of the infrared spectrum where the 
sample absorbs energy.  In the ATR spectra analysis, the energy absorption may 
appear as a combination of sharp or broad peaks, or as a combination of the two.  
There are a number of factors that affect the ATR analysis of a given sample.  
Amongst the these factors are the wavelength of the infrared radiation, refractive 
index of the ATR crystal material, depth of penetration of the evanescent wave 
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into the sample, thickness of the sample, and sample coverage on the ATR 
crystal.   
The FTIR-ATR spectra were recorded using a Nicolet Magna 550 FTIR-
spectrometer equipped with a single reflection diamond ATR system (Spectra-
Tech Inc., Oak Ridge, Tennessee).   In order to minimize the potential combined 
effect of these factors, a sample was loaded to a glass region and pressed down 
to promote small sample thickness and even distribution over the entire surface 
of the ATR crystal.  All spectra analyses were performed twice, with a total of 32 
scans each at a resolution of 4 cm-1. 
2.3 Cell culture 
 
A mammary gland epithelial cell line labeled with green fluorescent protein 
(GFP), designated MAC-T-R was to study the cellular response to fibers 
developed by the two encapsulation methods.  The cells were cultured at 
passages 19 and 23 in roller bottles (850 cm2, vented cap; Corning, Acton, 
Massachusetts) for 28 days.  These roller bottle cultures were incubated at 37°C 
and 5% CO2 in a CO2 controlled environment (Forma Reach-In CO2 Incubator, 
Thermo Electron Corporation, Waltham, Massachusetts).  Each roller bottle 
contained 35 mL of Dulbecco’s Modified Eagle's Medium (DMEM), supplemented 
with 10% (v/v) Fetal Bovine Serum (BioWhittaker; Walkersville, Maryland), 1% 
Antibiotic-Antimycotic (Invitrogen, Grand Island, New York), and 0.2% Fungizone 
(Invitrogen, Grand Island, New York). The bottles were rotated at 0.33 rpm using 
a roller culture apparatus (Wheaton, Millville, New Jersey).  The DMEM was 
changed every 5-7 days over the total culturing time.  During medium changes, 
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the cells in each roller bottle were rinsed with 10 mL of Phosphate Buffer Solution 
(PBS) to remove any remaining supplemented DMEM. 
2.4 Co-extrusion encapsulation procedure  
2.4.1 Preparation and sterilization of alginate and calcium chloride 
solutions 
 
Solutions of 90 mL and 500 mL 6 wt% (wt alg/wt distilled H2O) medium 
viscosity (MV) grade sodium alginate (Sigma, St. Louis, Missouri) were prepared 
by using an overhead stirrer (IKA®-WERKE; Eurostar Digital, Wilmington, NC).  
The distilled water was contained in Kimax® 200 mL and 1 L glass beakers 
(Kimble Kontes, Vineland, New Jersey) and stirred at a speed of 1000 min-1; the 
sodium alginate powder was gently added to minimize aggregation.  Once the 
powder was added, the solution was stirred at a speed of 2000 min-1 for 30 
minutes at room temperature.  The glass beakers containing the 6 wt% alginate 
solution were loosely covered with aluminum foil and placed inside of an 
autoclave-steam sterilizer (3870M Tuttnauer Autoclave-Steam Sterilizer; 
Tuttnauer Co. Ltd, Islip, New York).  The liquid sterilization cycle, which included 
a 15 minute depressurizing cycle, was conducted at 121°C for 1 hour.  The 
beakers were tightly covered with aluminum foil before transferring the beakers 
to a -20°C freezer for 1 hour to cool the solutions to room temperature.  A sterile 
spoon was used to stir 3 drops of water/propylene glycol based green food 
coloring (Assorted Food Colors & Egg Dye; McCormick & Co. Inc., Hunt Valley, 
Maryland) and 20 mL of supplemented DMEM into the 200 mL solution of MV 
alginate so that the acellular control fibers would be easily identifiable after the 
spinning process.   
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A 7 L solution of 15 wt% (wt CaCl2/wt distilled H2O) CaCl2 (Mallinckrodt & 
Baker Inc., Paris, Kentucky) was prepared by using an overhead stirrer (IKA®-
WERKE; Eurostar Digital, Wilmington, NC).  The distilled water was contained in 
a high density polyethylene 18.9L (5 gallons) bucket. The solution was stirred at 
a speed of 2000 min-1 for 1 hour.   
Three – 1000 mL glass media bottles were sterilized using a steam 
autoclave.  The media bottles were attached to 1L, 0.22µm polyethersulfone 
(PES) bottle top-filters (Corning, Corning, New York) and used to collect the 
vacuum filtered 15 wt% CaCl2.  As per product manual, specifications an 
additional 0.22 µm filter mesh was added to the filter unit to extend the use of the 
unit.  Three of the four units received an additional 0.22 µm filter mesh. 
2.4.2 Preparation and sterilization of spinning equipment  
 
A 16G injection needle (Becton Dickinson, Franklin Lakes, New Jersey) 
(EI#9) was modified by shortening the length of the needle to ¼ inches.  As listed 
in Table 2.1, equipment items 2-9 were placed inside the 60 cm basin, as shown 
in Figure 2.3.  The basin was sealed inside a 61 cm X 91.4 cm polyethylene 
autoclavable bag (VWR International, West Chester, Pennsylvania); and the 
equipment items were sterilized using an autoclave (3870M Tuttnauer Autoclave-
Steam Sterilizer; Tuttnauer Co. Ltd, Islip (Hauppauge), New York) at 121°C for 
30 minutes, followed by a 15 minute depressurization cycle.  The 16G needles 
were washed with LYSOL® all purpose cleaner (Reckitt Benckiser Inc., 
Parsippany, New Jersey), rinsed with hot tap water, and disinfected with 70% 
ethanol (Table 2.1).   
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Table 2.1: Description of equipment items used during the co-extrusion 
experiment 
Equipment Item 
Number Description of Equipment Item 
1 1-60 cm coagulation basin 
2 2-Teflon Rollers 
3 1-long handle gear key 
4 1- Assembled spinning apparatus 
5 1 spoon 
6 1-100 mL glass beaker 
7 2-500 mL glass beaker 
8 Silicone tubing (0.062ID X 0.125OD X 0.032 WALL) 
9 1-16G injection needles (modified) 
10 2 - large metal stands with attachment grips 
11 Chrome shaft air motor 
12 Syringe pump 
13 Wind-up roller 
14 2-1/2", 0-30psig pressure gauge 
15 2-1/2", 0-60psig pressure gauge 
 
 
 44
 
Figure 2.3: Preparation for the sterilization of the equipment items.  Equipment 
items used in the alginate fiber spinning process were cleaned with LYSOL® All 
Purpose Cleaner, dried, sprayed with 70% ethanol, and placed inside a pre-
cleaned basin.  
 
The modified lab cabinet (Class II Biological Safety Cabinet; The Baker 
Co., Sanford, Maine) was cleaned with Naval Jelly® rust dissolver/protector 
(Naval Jelly Co., Inc., Kansas City, Missouri).  The lab cabinet was then sprayed 
with a solution of 70% ethanol.  The lab bench was aligned with a double layer of 
white, cross-linked, polyethylene bench paper (Clean Sheets Bench and Shelf 
Liners; VWR International, West Chester, Pennsylvania).  The plastic tubing 
modifications (VWR International, West Chester, Pennsylvania), pressure 
indicators (Cole-Palmer, Vernon Hills, Illinois), syringe pump (kdScientific, New 
Hope, Pennsylvania), and air motor (Series M-00X; Ingersoll-Rand, Southern 
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Pines, North Carolina) were cleaned with 70% ethanol and set up in the lab 
cabinet.  The lab cabinet was then sterilized with ultraviolet (UV) light for 1 hour. 
The autoclave bag that contained the 60 cm basin was placed inside the 
lab cabinet.  The equipment items were removed from the basin and placed to 
the side in the lab cabinet.  The polyethylene wind-up roller (Memorex Products, 
Inc., Cerritos, California) (E#12) was sterilized with 100 % ethanol and set up in 
the lab cabinet.  The long handle gear key (EI#3) was used to tighten the wind-up 
roller onto the air motor.  The sterilized pre-assembled spinning apparatus 
(Figure 2.4), was setup inside of the lab cabinet securing the silicon tubing (EI 
#8) to the coagulant injection pin and to the modified 16G injection needle with 
copper wire (VWR International, West Chester, Pennsylvania).  The basin (EI#1) 
was filled with 6 L of sterile 15 wt% CaCl2.  The colored MV alginate solution was 
poured into the pot of the spinning apparatus and the top of the spinning 
apparatus was replaced and tightened.  The nitrogen supply line was connected 
to the spinning apparatus. The air gap, or the height of the spinning apparatus 
from the surface of the CaCl2 solution in the basin, was adjusted to 25 mm by 
using the adjustable clamp on the metal stands to reposition the spinning 
apparatus.    
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Figure 2.4: The fully assembled stainless steel (316) spinning apparatus.  The 
spinning apparatus features a nitrogen inlet line (A), 200 mL polymer loading 
chamber (B), ball valve equipped (shown in the fully close position) with a safety 
pin (C), coagulant or additive injection pin (D), and spinneret pack (E).   
 
2.4.3 Co-extrusion encapsulation procedure 
The acellular hollow fibers (control) were spun under the constant 
conditions shown in Table 2.2.  As the nascent filament was extruded, it was 
guided through the 15 wt% CaCl2 coagulation bath to the wind-up roller.  Once a 
steady alginate extrusion was established, the Telfon rollers were added to the 
bath to keep the fiber submerged in the bath as coagulant was pumped through 
the lumen of the fiber.  One roller was placed so that the nascent filament would 
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be guided perpendicularly through the bath to the extrusion axis.  These acellular 
fibers served as the controls for the experiment.  
To make the cellular fibers, 10 mL of supplemented Dulbecco’s Modified 
Eagle’s Medium (DMEM) solution (Gibco Invitrogen Corporation, Grand Island, 
New York) containing 3.2 X 109 MAC-T cells was prepared.  The cell suspension 
was pipetted (VWR International, West Chester, Pennsylvania) into the 90 mL 
solution of sterile MV alginate, decreasing the cell concentration to the desired 
density of 3.2 X 106 cells / mL of sodium alginate + supplemented DMEM.  A 
sterile spoon was used to thoroughly distribute the cells throughout the alginate.  
The even distribution was confirmed by adding 2 mL of the cell/alginate precursor 
solution to a 6-well plate and viewing the distribution through a blue fluorescent 
filter and microscope at 25x total magnification.    
A volume of 100 mL of the colored alginate solution was added to the 
spinning solution and used as a primer solution to establish the spinning 
conditions listed in Table 2.2.  A volume of 80 mL of the cell/alginate precursor 
solution was poured into the spinning pot.  The top of the spinning apparatus and 
the nitrogen supply line was replaced and tightened.  The air gap, or the height of 
the spinning apparatus from the surface of the CaCl2 solution in the basin, was 
re-adjusted to 7.5 cm by using the adjustable clamp on the metal stands to 
reposition the spinning apparatus.  The hollow fibers were spun under the 
constant conditions shown in Table 2.2.   
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Table 2.2: Description of constant spinning parameters used in the co-extrusion 
encapsulation method 
 
Spinning Parameter Description 
* Spinneret Size : 4 mm OD 1 mm ID, 2 mm OD capillary tube 
* Extrusion Nitrogen Pressure : 4.5 ±1 psig 
* Air Gap between Spinneret and Coagulant Bath : 25 mm 
* Room Temperature : 23°C, 30% humidity 
* Coagulant Bath Length : 60 cm 
* Coagulant Concentration  : 15% CaCl2 
* Coagulant Injection Rate : 15 mL/min 
* Wind-up Roller Pressure : 14 ±5 psig 
* Fiber storage : 15% CaCl2 
 
The fibers were removed from the 15% CaCl2 solution and cut into 1 - inch 
sections with a sterile razor blade (VWR International, West Chester, 
Pennsylvania).  Each completed fiber was placed into a well of a labeled 6-well 
plate that contained 5 mL of supplemented DMEM, the composition of which is 
specified in section 2.3 of this thesis.  The acellular and cellular fibers were 
incubated at 37°C and 5% CO2.   
A fiber section was cut in half and used for wet dimensional analysis.  The 
wet ½ inch section was placed upright onto a microscope slide (Colorfrost 
microslide; VWR International, West Chester, Pennsylvania).  A microphotograph 
was made using an inverted microscope and ProgRes CaptureBasic© software.  
Measurements of the fiber diameter and wall thickness were made with Image-
Pro Plus© software (Media Cybernetics, Inc., Silver Spring, Maryland).   
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2.5 Manual injection encapsulation procedure  
2.5.1 Preparation and sterilization of alginate and calcium chloride 
solutions 
 
A 100 mL stock solution of 0.74 wt% (wt alg/wt distilled H2O) LV alginate 
(Sigma, St. Louis, Missouri) was prepared using a stir bar (cylindrical, 1-inch 
length, Fisher, Fair Lawn, New Jersey) and magnetic stir plate (Corning, Acton, 
Massachusetts).  The distilled water was contained in a plastic 100 mL specimen 
cup and stir bar at a setting of 5 for 1 hour.  The 0.74 wt% alginate solution was 
sterilized by using a 0.2 μm sterile 100 mL polyethersulfone (PES) filter unit 
(Corning, Corning, New York).  The remainder of the alginate and calcium 
chloride solutions were prepared and sterilized as per section 2.4.1 of this thesis.   
2.5.2 Preparation and sterilization of spinning equipment  
 
The spinning equipment was prepared and sterilized as per section 2.4.2.  
The hollow fibers were spun under the constant conditions shown in Table 2.3. 
Table 2.3: Description of constant spinning parameters used in the manual 
injection encapsulation method 
 
Spinning Parameter Description 
* Spinneret Size : 4 mm OD 1 mm ID, 2 mm OD capillary tube 
* Extrusion Nitrogen Pressure : 5± 0.45 psi  
* Air Gap between Spinneret and Coagulant Bath : 25 mm 
* Room Temperature : 25 °C, 80% humidity 
* Coagulant Bath Length : 60 cm 
* Coagulant Concentration  : 15% CaCl2 
* Coagulant Injection Rate : 10 mL/min 
* Fiber storage : 15% CaCl2 
 
2.5.3 Manual injection encapsulation procedure 
The fibers were removed from the 15% CaCl2 solution and cut into 1-inch 
sections.  Curved sections were excluded to minimize fiber puncturing by the tip 
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of the injection needle tip.  The experiment setup for the manual injection 
encapsulation is shown in Figure 2.5.  The excess solution found in the lumen of 
the hollow fiber was aspirated using a sterile glass pipette (Fisher Scientific, 
Pittsburg, Pennsylvania).  The prepared 1-inch sections were placed in a sterile 
200 mL storage container filled with 15% CaCl2 solution.     
A
B C
D F
G
H
E
 
Figure 2.5: The experimental setup for the manual injection process.  The items 
used in the manual injection process included 1-inch hollow fiber sections stored 
in 15 wt% CaCl2 solution (A), sterile distilled water (B), supplemented DMEM (C), 
fiber end capping stations (D), a stock cell solution of 3.0 X 106 cells/mL 
DMEM+0.74 wt% LV alginate (E), a stock solution of sterile 0.74 wt% LV alginate 
(F), a syringe loaded with the stock cell solution (G), an incubation tray (H), and a 
stock solution of 15 wt% CaCl2 (not pictured). 
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Two 6-well plates (Corning, Corning, New York) were prepared by adding 
volumes 10 mL of filter sterilized 15 wt% CaCl2 solution and autoclaved 0.74 wt% 
sodium alginate to alternating wells of the plates, as shown in Figure 2.6.   
15wt% 
CaCl2
15wt% 
CaCl2
15wt% 
CaCl2
0.74wt% 
LV Alg
0.74wt% 
LV Alg
0.74wt% 
LV Alg
1 2 3
4 5 6
 
Figure 2.6: A 6-well plate served as the fiber capping station.  The numbers 
indicted denote the order in which the fibers were dipped.  Step 1 was repeated 
again for Step 7.  
 
A 2 mL supplemented Dulbecco’s Modified Eagle’s Medium (DMEM) 
solution (Gibco Invitrogen Corporation, Grand Island, New York) containing 6.4 X 
106 MAC-T cells was prepared and pipetted (VWR International, West Chester, 
Pennsylvania) into an autoclaved Kimax® 10 mL beaker (Kimble Kontes, 
Vineland, New Jersey).  A 2.1 mL aliquot of filter sterilized 0.74 wt% LV alginate 
was then added to the 10 mL beaker, decreasing the cell concentration to the 
desired density of 3.0 X 106 cells / mL of sodium alginate + supplemented 
DMEM.  The cell/alginate stock solution was thoroughly mixed using an 
autoclaved sterilized spoon (EI#5).  The stock solution was drawn into a sterile 
Luer Lock 3 cc syringe (Tyco Healthcare, Mansfield, Massachusetts) and an 
unmodified 16G 1 ½ injection needle was attached to the syringe and capped. 
 52
A fiber was removed from the distilled water using sterile tweezers.  The 
syringe unit was agitated manually to ensure the even distribution of the cells 
throughout the solution.  When the cell/alginate stock solution was injected into 
the fiber, the needle was inserted to half the length of the fiber and, as the lumen 
was filled, the needle tip was slowly moved toward the entrance end of the hollow 
fiber.  Each end of the fiber was hand-dipped three times into each well of the 
fiber capping 6-well plate at an approximate 45° angle, facilitating the production 
of a hollow fiber with bulbed ends.  Each bulbed fiber was placed into a well of a 
second 6-well plate that contained 5 mL of 15 wt% CaCl2 for 1 hour to gel the 
internal suspension matrix of LV alginate.  Each fiber was gently rinsed with filter 
sterilized distilled water to remove trace amounts of CaCl2 solution.   
The controls for this study consisted of 10 acellular fibers that were made 
by injecting filter sterilized 0.74 wt% LV alginate into the lumens of the fibers, 
capping the fiber ends and gelling the fiber internal suspension matrices in the 
manner specified previously.  Each completed fiber was placed into a well of a 
labeled 6-well plate that contained 5 mL of supplemented DMEM, the 
composition of which is specified in the Cell Culture section of the Methods 
section of this thesis.  The acellular and cellular fibers were at 37°C and 5% CO2.  
A fiber section was cut in half and used for wet dimensional analysis, as per 
section 2.4.3 of this thesis.     
2.6 Cell response 
2.6.1 Validating the expression of green fluorescent protein (GFP) 
Green fluorescent protein (GFP) is a 27-kD monomer consisting of 238 
amino acids.  Labeling cells with GFP is a versatile tool for studying gene 
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expression in mammalian cells.  GFP can be monitored in living cells9-11.  It is 
superior to other biolumininiscent reporter assays, such as Live/Dead, that 
require the co-incubation of cells with substrates or co-factors to emit light.   
GFP expression was examined using the blue fluorescent filter on an 
inverted fluorescent microscope (Carl Zeiss MicroImaging, Inc., Thornwood, New 
York) at 25X total magnification on days 1, 5, 7, 10, 14, 18, and 21 of the study. 
2.6.2 Lactic acid and glucose measurement 
 
Single aliquots of 1 mL were pipetted into micro-centrifuge tubes (VWR 
International, West Chester, Pennsylvania) and collected from six sample wells 
and three control wells.  Also, a 1 mL aliquot was collected from a stock solution 
of supplemented DMEM at each time point before a media change occurred, in 
order to quantify the MAC-T production of lactic acid and consumption of 
glucose.  From these measurements, the amount of alginate dissolution that 
occurred throughout the study was calculated.  The measurements were 
completed using a bioanalyzer (YSI, Yellow Springs, Ohio).  The bioanalyzer 
uses a three filter layer + platinum electrode system to quantify each of the 
analytes.  The filter layers are comprised of a polycarbonate layer, immobilized 
enzyme layer, and cellulose acetate layer.  The enzyme filter layer contains 
glucose oxidase and L-lactate oxidase.  These enzymes oxidize glucose and 
lactic acid molecules into D-glucono-δ-lactone + hydrogen peroxide (H2O2) and 
pyruvate + hydrogen peroxide (H2O2), respectively.  The hydrogen peroxide is 
further oxidized and produces a stream of electrons.  These electrons are 
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amplified and conditioned as a current.  The current is compared to the 
calibration current and a glucose and lactic acid concentration is assigned.  
2.6.3 Alamar Blue reduction assay 
 
Metabolic activity of the viable encapsulated cells was measured using 
alamarBlue™ Reduction Assay (Invitrogen, Carlsbad, California).  The assay 
reagent can be reduced intracellularly by accepting electrons from hydrogen 
molecules that are present in higher quantities during cellular respiration and 
glucose metabolism.  Upon reduction, alamarBlue changes from an oxidized 
indigio blue, non-fluorescing state, to a reduced pink fluorescent state.  The 
major difference between the MTT assay and alamarBlue™ is that alamarBlue™ 
does not lead to cell death12.  The cell metabolic activity can be then be 
correlated and monitored spectrophotometrically either by color measurement or 
fluorescence. 
A volume of 400µL of the alamarBlue assay was pipetted into one well 
that contained an acellular control fiber surrounded by 4 mL of supplemented 
DMEM and into three wells that each contained a cellular fiber for each time 
point.  The well plates containing the assay were incubated at 37°C and 5%CO2 
for 4 hours.  The assay/medium solution in each well was mixed by pipetting the 
solution from the well into a 3 mL sterile syringe (Tyco Healthcare Group, LP, 
Mansfield, Massachusetts) and back into the well three times.  A volume of 3 mL 
of the assay/medium solution was transferred to a well of a 24-well plate, where 
the mixing procedure was repeated.  After emptying the syringe into the well 
plate for the third time, the syringe was filled with 3 mL of the mixture.  A 0.2 µm, 
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25 mm Telfon syringe filter (Fisher, Fair Lawn, New Jersey) was attached to the 
syringe tip.  Wetting the syringe filter required 0.4 mL of solution.  A 1mL volume 
of the mixture was added at a slow and constant rate to another well of the 24-
well plate.  Aliquots of 100 µL of the filtered solution were pipetted into wells on a 
polystyrene 96-well plate (Corning, Corning, New York) in triplicate.  This 
procedure was used for the assay/medium solution that surrounded the acellular 
and cellular fibers on days 1, 7, 10, 14, 18 and 21.  The 96-well plate was 
inserted into the plate reader of a spectrophotometer (Fluoroskan Ascent FL; 
Thermo Electron Inc., Milford, Massachusetts) and the fluorescence from the 
alamarBlue reduction was measured using the Ascent© software version 2.4.2 
(Fluoroskan Ascent FL; Thermo Electron Inc., Milford, Massachusetts) at a filter 
pair wavelength of 544 (excitation) and 590 nm (emission).  
2.6.4 Alginate cellular fiber dissolution/cell counting 
The feasibility of the two cell encapsulation methods was studied by 
observing the change in cell number during 21 days.  At days 1, 7, 14, and 21, 
the alginate fiber was dissolved by removing the fibers from cell culture, 
removing excess DMEM remaining in the lumen of the fiber, and exposing the 
fibers to Dulbecco’s Phosphate Buffered Saline (Sigma-Aldrich, St. Louis, MO) in 
washing wells for 10 minutes (co-extruded fibers) and 12 minutes (manual 
injected fibers), as shown in Figure 2.7.  After swelling and softening, each fiber 
was transferred into a 1.5 mL micro centrifuge tube (VWR International, West 
Chester, PA).  Volumes of 1.5 mL of 55 mM sodium citrate (Fisher Scientific 
Company, Fair Lawn, New Jersey) were pipetted into each centrifuge tube.  The 
centrifuge tubes were placed in a preheated vacuum oven (National Appliance 
 56
Company, Winchester, Virginia) at 45°C ± 2°C for 45 minutes.  This temperature 
was reached using an oven temperature setting of 1.3.  After 45 minutes had 
passed, the tubes were checked for near total fiber dissolution.  The tubes were 
replaced in the oven for additional dissolution time, as needed.  A 101-1000 µL 
sized pipette tip (Fisher Scientific Company, Fair Lawn, New Jersey) and a 
pipetter (Eppendorf; VWR International, Wester Chester, PA) was used to mix 
the contents of the tube in 500 µL increments.  Maintaining the pipette tip at the 
0.5 mL marker, a 1-100 µL pipette tip (Fisher Scientific Company, Fair Lawn, 
New Jersey) and pipetter (Fisher Scientific Company, Fair Lawn, New Jersey) 
were used to pipette 20 µL of the mixed cell solution into a new 1.5 mL micro 
centrifuge tube.  A 1-100 µL pipette tip was used to add 20 µL of Modified Trypan 
Blue cell viability assay solution (MP Biomedicals, Inc, Solon, Ohio) to the cell 
solution. The cell suspension and assay solution were mixed by triturating three 
times.  Placing the pipette tip at the bottom of the centrifuge tube, 20 µL of 
mixture were transferred to a hemacytometer (Fisher Scientific Company, St. 
Louis, Missouri), and the cells were counted at a total magnification of 100 X on 
an inverted light microscope (Carl Zeiss MicroImaging, Inc., Thornwood, New 
York).  
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Figure 2.7: Fibers were soaked in a PBS bath to initialize the alginate dissolution 
process for 10 – 12 minutes.  The PBS bath swelled the fibers and decreased 
their mechanical integrity by replacing the calcium crosslinking cations with 
sodium cations. 
 
2.7 Histology 
2.7.1 Hollow fiber embedding 
A single hollow fiber was embedding into a glycol methacrylate (GMA) 
(Technovit 7100: GMA Embedding Agent; EB Sciences, East Granby, 
Connecticut) matrix using the experimental design and corresponding GMA 
embedding procedure, as shown in Figure 2.8 and Table 2.4, respectively. Steps 
1 & 2 were conducted to fix the cells and preserve the fiber morphology.  Steps 3 
– 12 were implemented to infiltrate the fiber with GMA in a stepwise manner.  
Steps 13 & 14 were employed to embed the fiber into liquid GMA solution, which 
was allowed 48 hours to polymerize.  Volumes of 10 mL volumes were used in 
Steps 1 - 12.  Six well plates with ¼ -inch stir bars in each well served as 
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infiltration stations and were placed on a Corning Stirrer/Hot Plate as specified in 
Figure 2.8. The experiment was conducted at ambient temperature, 22°C, 
without vacuum.    
The procedure was adapted from a previously described GMA embedding 
technique for alginate based beads13.  The normal two hours fixation time was 
decreased to 5 minutes because it was noted that the 10% Neutral Buffered 
Formalin (NBF) caused the fiber to swell. An additional step (Step 2) was used to 
dehydrate and preserve the fiber morphology by removing the majority of water 
from the fiber. “Solution A” that was used in step 13 was twice the concentration 
found in previously described methods from our lab. The hardener concentration 
was increased to improve the durability of the fiber throughout the rigorous 
staining procedure.   
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Table 2.4: Glycol methacrylate embedding procedure 
 
Step Time  
 min Solution 
1 2 10% NBF 
2 5 100 % ethanol 
3 5 10% GMA 
4 5 20% GMA 
5 5 30% GMA 
6 5 40% GMA 
7 5 50% GMA 
8 5 60% GMA 
9 5 70% GMA 
10 5 80% GMA 
11 5 90% GMA 
12 15  100 % GMA 
13 15 
0.02%(w/v) Solution A (0.06g of 
Hardener 1 + 3 mL of 100% GMA) 
14 5 
15 to 1 solution of 
Solution A to Hardener II 
Total time 87  
 
 
 
Figure 2.8: GMA embedding protocol. 
 
2.7.2 Centrifuge tube sectioning 
The GMA solution completely polymerized after 48 hours in a micro 
centrifuge tube.  The centrifuge tube was cut into three cylindrical sections using 
an automatic band saw (Delta International Machinery Corporation, Pittsburgh, 
PA), which yielded a cylindrical block of interest for further histological analysis.  
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The plastic from the centrifuge tube was cut and removed using a single edge 
No. 12 industrial razor blade (VWR Scientific, Media, PA).  A micrograph was 
taken of the cross section of one of the fiber sections. 
2.7.3 Micro-sectioning 
Using a microtome (Leica RM 2155, Leica Microsystems, Germany), 30 
micron sections were obtained from the fiber block.  To uncurl the sections, the 
sections were floated on the surface of a water bath at 35 - 37°C.  The sections 
were retrieved from the water bath on glass microscope slides.  The slides were 
transferred onto a flat plate dryer to remove excess water.  After drying, a slide 
was selected for high magnification light microscopy.  A drop of mineral oil and a 
coverslip was added to each slide in order to improve viewing quality.     
2.7.4 Toluidine blue dying method 
A volume of 0.5 – 1 mL 95% ethanol was pipetted onto the fiber cross 
section.  Toluidine Blue was pipetted on the cross section on the glass 
microscope slide and left for 5 minutes.  Excess dye was removed from the 
microscope after 2.5 minutes by gently tapping the side of the microscope slide 
on absorbent gauze. The slide was then rinsed in a gentle flow of distilled water 
to clarify the stain, as needed.  Additional 95% ethanol was applied to the cross 
section to further distinguish the pink staining alginate from the blue staining 
cells.  A temporary coverslip was added to one slide by using a non-sterile 1 mL 
pipetter to apply a drop of water after the cross section was dyed, clarified, and 
sprayed with ethanol. 
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2.7.5 Cell area and axial dimension analysis 
 
Alginate fibers were embedded into glycol methacrylate (GMA) on Days 1, 
7, 14 and 21.  Sections of these fibers were stained using toludiene blue.  An 
inverted microscope (Axioskop 2 Plus; Car Zeiss MicroImaging, Inc., Thornwood, 
New York) and software (SPOT© Version 3.5.9 for Windows; Diagnostic 
Instruments, Inc., Sterling Heights, Michigan) were used to create 
microphotographs of the stained sections at total magnifications of 100 and 
200X.  Axial measurements of 20 randomly selected encapsulated cells were 
measured on each micrograph using the Image-Pro© 5.1 software 
(MediaCybernetics, Silver Spring, Maryland).  The x and y axis was assigned as 
the shortest and longest axis of the oval shaped cells.  These axial 
measurements were converted into a Y/X ratio as an indication of diameter and 
implemented into the calculation of cell area using elliptical geometry (Cell Area = 
π * 0.25 * x * y).   
2.8 Statistical analysis 
 
Statistical analysis was conducted using a two-factor with replication 
ANOVA test in Microsoft Excel© for the C/A ratio and cell number data sets, 
whereas a one-factor ANOVA test was used to conduct statistical analyses on 
the Y/X ratio, cell area, and daily MAC-T lactic acid production and glucose 
consumption data sets.  A Fisher’s Least Significant Difference (LSD) calculation 
was made to supplement the ANOVA tests in which there was sufficient evidence 
(i.e p<0.05 or F>Fcrit) to reject the null hypothesis of equal means with a 95% 
confidence level.   Box and whisker plots were created in Microsoft Excel© to 
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show the dispersion and variability of those data sets in which there was 
sufficient evidence (i.e. p>0.05 or F<Fcrit) to accept the null hypothesis of equal 
means with 95% confidence.  
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CHAPTER THREE 
 
RESULTS 
 
 
3.1 Sodium alginate solution properties 
3.1.1 Molecular weight distribution 
 
A linear trend-line was fitted to the inherent viscosity plot for each alginate 
type.  It was observed that as the sodium alginate concentration approaches zero 
the AO and LV alginates approaches the same intrinsic viscosity value, as shown 
in Figure 3.1.  The MV alginate however has an intrinsic viscosity that is twice as 
much as the other two alginate types.  The inherent viscosity plot and intrinsic 
viscosities per alginate type obtained at a shear rate of 38.6 sec-1 are given 
below in Figure 3.1 and Table 3.1, respectively.  
Also, it was determined that the calculation of the viscosity average 
molecular weight is dependent upon the shear rate at which the apparent 
viscosity is assessed.  A median molecular weight was calculated from the 
molecular weight distribution (Figure 3.2 and Table 3.2).  It was determined that 
MV sodium alginate has the greatest median molecular weight value (284 kDa), 
followed by AO sodium alginate (212 kDa), and LV sodium alginate (187 kDa).   
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Figure 3.1: Inherent viscosity of sodium alginate at a shear rate of 38.6 sec-1.  
This figure depicts the inherent viscosity results for the three alginate types: MV 
(▲), AO (●) and LV (■).  The error bars indicate the standard error. 
 
Table 3.1: Intrinsic viscosity and viscosity average molecular weight data per 
alginate type at a shear rate of 38.6 sec-1 
 
 Intrinsic viscosity Molecular weight 
 η MW 
Alginate type dL/g kDa 
MV 7.74 387 
AO 3.34 167 
LV 2.79 140 
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Figure 3.2: A box and whisker plot for the sodium alginate molecular weight 
distribution. 
 
Table 3.2: Statistical analysis of sodium alginate molecular weight distribution 
 
 LV AO MV 
 MW MW MW 
Statistic kDa kDa kDa 
Max 270 322 506 
Q3 206 264 402 
Median 187 212 284 
Q1 140 150 185 
Min 117 59 139 
Coefficient of Variation, % 30 46 46 
 
3.1.2 Viscosity profile of three alginate types    
 
A viscosity – concentration profile of low (LV), medium (MV) and Acros 
Organics (AO) viscosity grades of sodium alginate was created by plotting the 
apparent viscosity as a function of the concentration of the sodium alginate at a 
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shear rate of 100 s-1 (Figure 3.3).  It was observed that the apparent viscosity of 
sodium alginate increases exponentially as the concentration of sodium alginate 
increases.  The exponential behavior is typical for non-Newtonian, pseudo-plastic 
fluids and is best described as a power law function.  The empirical equations 
that describe the relationship between apparent viscosity in centiPoise (y) and 
alginate concentration in weight percentages (for MV, AO, and LV viscosity 
grades are y = 152.66x2.577, R2 = 0.9874; y = 28.524x3.0578, R2 = 0.9974; and, y = 
18.405x2.6745, R2 = 0.9901, respectively.  It is important to note that these 
equations are simplified in that they do not include the apparent viscosity of DD 
water at 25 °C (0.89 cP), which is negligible in comparison to the viscosity of 
concentrated sodium alginate solutions.  The viscosity profile of the three 
alginate types shows that at 6 wt% MV has an apparent viscosity of    15,000 cP.  
It was at this viscosity that the optimal fiber spinnability occurred using the motor 
powered extrusion system.  Comparatively, the apparent viscosities of AO and 
low viscosity LV alginate at a concentration of 6 wt%, are approximately 6800 
and 2200 cP, respectively.  A summary of the measured apparent viscosity at 2 
% has been noted and compared to literature value data (Table 3.3).  Creating 
the viscosity profile facilitated the visualization of the dependency of sodium 
alginate on concentration and shear rate, as shown in Figure 3.4.   
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Figure 3.3: The effect of sodium alginate concentration on apparent viscosity at a 
shear rate of 100 s-1.    
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Figure 3.4: The effects of sodium alginate concentration and shear rate on 
medium viscosity sodium alginate’s apparent viscosity.  The apparent viscosity is 
shown as the slope of the concentration plots.  MV alginate displays a viscosity 
behavior that decreases with respect to an increasing shear rate.   
 
Table 3.3: Solution properties of sodium alginate 
 
Viscosity 
Grade 
Viscosity 
Literature Values 
@ 2%, 25°C, (cP)
Measured 
Viscosity 
Values @ 
2%, 25°C, (cP)
Molecular 
Weight 
Literature 
Values, 
(kDa) 
Viscosity Average 
Molecular Weight 
Range, 
(kDa) 
MV 3500 910 120-180 153-382 
AO 510 240 2000 185-254 
LV 250 120 80-120 151-247 
 
3.1.3  Autoclaving and DMEM addition on alginate’s viscosity 
 
In addition to determining the effects of concentration and molecular 
weight on the viscosity profiles of the three types of alginate, it was also desirable 
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to determine the effects of autoclaving and adding DMEM to provide nutritional 
value to alginate.  The intent of this characterization was to establish a viscosity 
range in which hollow fibers could be fabricated under the same coagulant bath 
concentration, extrusion pressure, and coagulant injection rate.   
The results indicate that autoclaving 6 wt% MV sodium alginate at 121 °C 
for 1 hr and cooling to room temperature reduces its apparent viscosity by 50% 
from 11,000cP to 5,500 cP.  The outcome of this study also suggests that 
preparing a 1:1 solution of autoclaved 6 wt% MV alginate and DMEM decreases 
the viscosity even further to 250 cP.  However, if a 10:1:: autoclaved 6 wt% MV 
alginate and DMEM solution is prepared, the apparent viscosity of the autoclaved 
6 wt% alginate is only reduced by to 3,600 cP, as shown in Figure 3.5.   
The Effects of Autoclaving and Adding Dulbecco’s Modified Eagle’s 
Medium (DMEM) on the Apparent Viscosity of Sodium Alginate @ 100 1/s.
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Figure 3.5: The effect of autoclaving and adding DMEM to 6 wt% MV sodium 
alginate. 
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3.1.4  M/G block ratio 
 There is an inverse relationship between P/T ratio and %G block (Figure 
3.6). The G block percentages from Methods 1 and 2 indicate that the %G block 
from MV, AO, and LV alginate range from 45 and 47%, 38 and 41%, and 44 and 
48%, respectively.  Method 3, however, suggests that the %G block is 70, 69, 
70% for MV, AO, and LV alginate, respectively, as shown in Figure 3.7.  The 
vibration of several functional groups and bonds that are specific to alginate 
monomers are summarized in Table 3.4.  Analyses conducted by a One-way 
ANOVA test conclude with a 95% confidence level that there is no difference 
between the G block percentages generated by using Method 1 versus Methods 
2.  However, an additional One-way ANOVA test suggests that there is a 
significant difference between the average M/G ratios calculated via Methods 1 
and 2 and the M/G ratios that were determined using Method 3.     
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Figure 3.6: Determining the %G block of three alginate types.  The linear portion 
of the P/T Ratio correlation chart (Eq. 2.5) was used to determine the % G block 
for AO (blue), MV (red) and LV (green) sodium alginate (Method 2).
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Figure 3.7: FTIR-ATR spectra showing similar functional groups and bond vibrations for three alginate types. 
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Table 3.4: Wavenumbers of key alginate functional groups and bonds, as  
cataloged in the literature1-3  
 
Wavenumbers at major 
absorbance peaks 
Functional group(s) and 
bonds with associated 
vibration 
cm-1  
3300 Hydroxyl (-OH) 
1600 Carboxylic acid (COO-) 
1400 Carboxylic acid (COO-) 
1297 C-O bond 
1176 C-O bond 
1122 C-C or C-O bond 
1084 C-O-C ester bond 
1028 C-OH bond 
950 (-OH) or C-C-H bond 
 
 
Table 3.5: Comparison of M/G ratio and % G block via three methods for three  
types of alginate 
 
MV 0.61 1.22 45 1.13 47 0.43 70
AO 0.81 1.62 38 1.44 41 0.45 69
LV 0.57 1.14 44 1.08 48 0.43 70
%G%G
M/G 
Ratio
Method 2 Method 3
M/G 
Ratio
Method 1
Viscosity 
Grade
P/T 
Ratio
M/G 
Ratio %G
 
 
 
3.2 Cellular response 
3.2.1 Lactic acid production 
 
It was observed that the lactic acid produced by MAC-Ts encapsulated in 
CO-X type fibers (n=6 for Days 0-5, n=12 for Days 10-21) initiated at Day 5, 
whereas the production of lactic acid initiated at Day 1 in MI type fibers (n=6), as 
shown in Figure 3.8.  The MAC-Ts within each fiber type produce similar 
amounts of lactic acid.   
 
   75
A One-Factor ANOVA test was employed to compare the average lactic 
acid productions on Days 1, 5, 10, 14, 18, and 21 for each encapsulation 
method.  It was observed that there was no significant difference in the means of 
lactic acid production between time points within the MI (n=6) or CO-X (n=12) 
encapsulation study. These observations were confirmed by a corresponding p-
value of 0.7142. Based on our sample size and procedure of measurement, it 
can be concluded with a 95% confidence level that there is no evidence to 
suggest that there is a difference in the average lactic acid production within 
each encapsulation method during Days 1, 5, 10, 14, 18, and 21.   
One can observe that the distribution of daily MAC-T lactic acid production 
is skewed to the right for both methods.  Although the skew of the lactic acid 
production in the MI method maintains as time progresses, the skew of the lactic 
acid production in the CO-X method increases with time (Figure 3.9 and Table 
3.6).  It is important to note that the skew of the lactic acid production values in 
the CO-X type fiber data set may have been influenced by an increased sample 
size.   
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Figure 3.8: The accumulation of lactic acid produced by encapsulated MAC-Ts. 
Error bars express standard deviations.   
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Figure 3.9: Box and whisker plot of the MAC-Ts’ daily production of lactic acid for 
the MI (n=6) and CO-X (n=6 for Days 0-5, n=12 for Days 10-21) encapsulation 
methods.  
 
3.2.2 Glucose consumption 
Overall, there were noticeable differences between the two encapsulation 
groups in the MAC-Ts’ glucose consumption behavior (Figure 3.10 and Table 
3.7).  A greater lag time for MAC-Ts’ consumption of glucose under the CO-X 
(n=6 for Days 0-5, n=12 for Days 10-21) encapsulation method; however, it 
appears that MAC-Ts encapsulated in the CO-X type fibers consumed more 
glucose than MAC-Ts encapsulated in the MI type fibers by Day 21 of the study.  
It was also observed that the glucose consumed by the MAC-Ts in the MI type 
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fibers (n=6) accumulates linearly, whereas the glucose consumed by the MAC-Ts 
in the CO-X fibers accumulates exponentially.   
A One-Factor ANOVA test was performed to compare the average 
glucose consumption from days 1, 5, 10, 14, 18, and 21 for each encapsulation 
method (Figure 3.11).  There was no significant difference in the means of 
glucose consumption between time points within each encapsulation group, as 
confirmed by the p-value of 0.7532.  Based on our sample size and procedure of 
measurement, it can be concluded with a 95% confidence level that there is no 
evidence to suggest differences in the values for the average glucose 
consumption at each time point within each encapsulation method.   
Notice that the values of the means of the daily consumption in the CO-X 
study are higher than the medians of the data, which indicates that the glucose 
consumption distribution is highly skewed to the right (Figure 3.11).  Although the 
distribution of MAC-T glucose consumption values within the MI type fibers is 
slightly skewed to the right, the distribution does not vary greatly from Days 5 to 
21, which corresponds to the linear accumulation of the glucose consumed by 
MAC-Ts in the MI type fibers, as shown in Figure 3.10.     
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Figure 3.10: The accumulation of glucose consumed by encapsulated MAC-Ts. 
Error bars express standard deviations.   
 
 
 
   
 
Figure 3.11: Box and whisker plot of the MAC-Ts’ daily consumption of glucose 
for the MI (n=6) and CO-X (n=6 for Days 0-5, n=12 for Days 10-21) 
encapsulation methods.  
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MI CO-X MI CO-X MI CO-X MI CO-X MI CO-X MI CO-X MI CO-X
g/L g/L g/L g/L g/L g/L g/L g/L g/L g/L g/L g/L g/L g/L
25th percentile 0 0 0.40 0.16 0.39 0.19 0.39 0.19 0.39 0.21 0.39 0.19 0.39 0.19
50th percentile 0 0 0.40 0.19 0.40 0.19 0.40 0.19 0.40 0.24 0.40 0.31 0.40 0.37
75th percentile 0 0 0.40 0.19 0.40 0.19 0.40 0.20 0.40 0.36 0.40 0.55 0.40 0.66
Interquartile range 0 0 0 0.03 0.01 0 0.01 0.01 0.01 0.15 0.01 0.36 0.01 0.47
Interquartile mean 0 0 0.40 0.19 0.40 0.19 0.40 0.19 0.40 0.30 0.40 0.45 0.40 0.50
Mean 0 0 0.39 0.15 0.39 0.18 0.39 0.20 0.39 0.28 0.39 0.44 0.39 0.47
Minimum 0 0 0.36 0.00 0.36 0.15 0.36 0.19 0.36 0.19 0.36 0 0.36 0
Maximum 0 0 0.41 0.20 0.40 0.20 0.40 0.22 0.40 0.41 0.40 1.46 0.40 1.46
Day 14 Day 18 Day 21Day 0 Day 1 Day 5 Day 10
 
MI CO-X MI CO-X MI CO-X MI CO-X MI CO-X MI CO-X MI CO-X
g/L g/L g/L g/L g/L g/L g/L g/L g/L g/L g/L g/L g/L g/L
25th percentile 0 0 0 0 0.078 0.004 0.101 0.017 0.111 0.021 0.126 0.043 0.177 0.051
50th percentile 0 0 0 0 0.079 0.006 0.102 0.020 0.115 0.031 0.147 0.055 0.199 0.064
75th percentile 0 0 0 0 0.087 0.015 0.132 0.032 0.148 0.041 0.172 0.089 0.232 0.118
Interquartile range 0 0 0 0 0.009 0.011 0.031 0.015 0.037 0.020 0.046 0.046 0.055 0.067
Interquartile mean 0 0 0 0 0.083 0.008 0.118 0.027 0.134 0.051 0.170 0.084 0.227 0.099
Mean 0 0 0 0 0.082 0.010 0.115 0.024 0.129 0.076 0.160 0.116 0.202 0.129
Minimum 0 0 0 0 0.077 0.001 0.096 0.005 0.111 0.005 0.113 0.026 0.134 0.030
Maximum 0 0 0 0 0.087 0.023 0.144 0.038 0.154 0.416 0.219 0.551 0.245 0.566
Day 14 Day 18 Day 21Day 0 Day 1 Day 5 Day 10
 
Table 3.6: Data summary of Figure 3.8: Daily MAC-T lactic acid production plot 
Table 3.7: Data summary of Figure 3.9: Daily MAC-T glucose consumption 
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3.2.3 Alamar blue reduction 
The C/A ratio of both fiber types appeared to fluctuate around a value of 1 
during the 21 day study.  A Two-Factor With Replication ANOVA test and 
Fisher’s Least Significant Difference (LSD) protocol was employed to compare 
the average C/A ratio at Days 1, 7, 14, and 21 of each encapsulation method 
(Figure 3.12).  A significant difference was observed within the MI type fibers for 
the C/A ratios between Days 1 and 5, 1 and 10, 1 and 14, 1 and 18, and 1 and 
21.  A significant difference was also observed within the CO-X study for the C/A 
ratios between Days 1 and 5, 1 and 14, 1 and 18, 1 and 21, 10 and 18, 10 and 
21, 14 and 18, and 14 and 21.  The p-value corresponding to the ANOVA test 
used to analyze the C/A ratio data was 0.0072 (n=3).  The p-value associated 
with the interaction between the two encapsulation methods was 1.53E-07, 
suggesting that there was a significant change in the differences of the two 
encapsulation methods throughout the study.  Therefore, no conclusion can be 
made about which method gives higher C/A results, and no implications can be 
made about the MAC-T’s metabolism of glucose or viability using this study.   
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Figure 3.12: Ratio of the fluorescence in cellular ( C ) and acellular ( A ) alginate 
fibers for the MI and CO-X (n=9, cellular and n=3, acellular) for both 
encapsulation methods.  The error bars indicate standard deviation.   
 
3.2.4 Cell number 
A Two-Factor With Replication ANOVA test was employed to compare the 
average cell count performed on Days 1, 7, 14, and 21 of each encapsulation 
method (Figure 3.13).  It was noticed that there was no significant difference in 
the average cell number between time points for either the MI or the CO-X 
encapsulation study.  The lack of a significant difference was validated by a p-
value of 0.2450 (n=2).  It was also observed that there was no significant 
difference between the cell numbers counted between encapsulation methods.  
The p-value associated with the interaction between the two encapsulation 
methods (p = 0.708) suggests that there is not a significant difference in the 
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change between the two encapsulation methods throughout the study, as shown 
in Figure 3.13.  The uncontrolled error (MSE) was 1.68E+11, which suggests that 
a larger sample size should be used with a hemacytometer.  Therefore, it can be 
concluded with a 95% confidence level that based on our sample size and 
procedure of measurement, there is no evidence to suggest that the average cell 
numbers found at Days 1, 7, 14, and 21 are different. However, one can observe 
that there is much higher variability in the measurements made on Day 21 than 
the measurements made on Day 1 of the study.   
Cell count for MI and CO-X encapsulation methods
0.0E+00
5.0E+05
1.0E+06
1.5E+06
2.0E+06
2.5E+06
0 7 14 21
Time, day
N
um
be
r o
f c
el
ls
 /i
n.
 fi
be
r, 
ce
lls
/in
.
CO-X cell count
MI cell count
Cell Count for MI and CO-  E capsulation Methods
Time, days
CO-X MI
N
um
be
r o
f c
el
ls
 /i
n.
 fi
be
r, 
ce
lls
/in
.
 
Figure 3.13: MAC-T cell count performed via hemacytometer.  MAC-T cell count 
for MI (n=4) and CO-X (n=2) encapsulation methods over 21 days.  The error 
bars denote the standard deviation.  
 
3.2.5 The expression of green fluorescent protein (GFP) 
 
 Fluorescent microscopy was used to qualitatively analyze the expression 
of GFP for both fiber types on Days 1, 10, 14, and 21 (Figure 3.14).  In the 
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analysis, the micrographs captured on Day 1 were used as the basis of 
comparison within each fiber type.  No noticeable decrease in GFP expression 
by the MAC-Ts inside each type of fiber was observed.  Also, it is important to 
note that the expression of GFP allowed one to observe the differences in the 
location and distribution of MAC-Ts between the two encapsulation methods.  In 
the CO-X fiber type, the cells were distributed in the fiber wall; whereas, the 
MAC-Ts were located in the lumen of the MI type fibers.    
 
Figure 3.14:  The expression of GFP for Days 1, 10, 14, and 21 of the MI (A-D) 
and CO-X (E-H) encapsulation studies.  The total magnification is 25X for all 
pictures. 
 
3.2.6 Histological processing  
 
Histological processing was completed by subjecting 30 micron sections 
of GMA embedded hollow fibers of both the MI (Figures 3.15 – 3.17) and CO-X 
(Figures 3.18 – 3.21) encapsulation methods to toluidine blue staining.  These 
fibers were removed from culture on Days 1, 7, 14, and 21. Cells could not be 
distinguished on a MI type fiber that had been removed from culture on Day 7 
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and no micrographs were made of its sections.  In general, the staining process 
enabled the cells to be labeled blue and the alginate pink or dark purple, 
depending on the concentration of the alginate.   
After one day in culture, the geometry of the MI type hollow fiber was been 
compromised, but the wall thickness has been maintained (Figure 3.15).  Notice 
that little to no cell aggregates are present within the internal cell suspensions.  
The embedding matrix has not been maintained and appears to be stretched. 
 
Figure 3.15: Day 1 toluidine blue staining pictures of MI encapsulated MAC-Ts.  
Total magnifications are indicated.    
Day 1 – 25X 
Day 1 – 200XDay 1 – 100X
Day 1 – 100X
 D 
 C 
 B 
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 Relative to Day 1, less of the cell suspension is present within the lumen 
of the MI type fiber on Day 14 (Figure 3.16A).  It is evident that the embedding 
method is not sufficient to maintain the in vitro morphology of the hollow fiber, 
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because the wall of the hollow fiber has been compromised (Figure 3.16B).  The 
cells that are present in the alginate matrix within the lumen of the hollow fiber 
conform to the cobblestone morphology present at various locations within the 
human body, such as the simple squamous epithelium on the surface of 
peritoneal mesothelium, the transitional epithelium of the contracted bladder, and 
the epithelial cells that surround the mammary gland (Figure 3.16B and Figure 
3.16D).  An alginate “string” has left the lumen, but remains attached to the 
hollow fiber wall (Figure 3.16C), which suggests that during the embedding 
process, the fiber ends do not remain capped and allow part of the cell 
suspension to escape.  It appears that the cells have released an anchoring 
matrix (Figure 3.16D).   
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Figure 3.16: Day 14 toluidine blue micrographs of MAC-Ts (blue) encapsulated in 
a 0.74 wt% alginate suspension matrix (black and dark purple) and MI 
encapsulated MAC-Ts.  Total magnifications are indicated.   
Day 14 – 25X
Day 14 – 200XDay 14 – 100X
 D 
 C 
 B 
 A 
Day 14 – 100X
 
Micrographs were taken of the cell and fiber morphology of the MI type 
fiber on Day 21 (Figure 3.17).  These micrographs reveal that the same GMA 
embedding and histological processing techniques have a greater affect on the 
fiber morphology as time progresses (Figure 3.17A & Figure 3.17D).  The 
micrographs also reveal few cell aggregates and more dissolution of the internal 
suspension matrix (Figure 3.17B & Figure 3.17C). 
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Day 21 – 25X
Day 21 – 100XDay 21 – 100X
 D  B 
 C  A 
Day 21 – 100X
Figure 3.17: Day 21 toluidine blue staining pictures of MI encapsulated MAC-Ts.  
Total magnifications are indicated.   
 
 
 Histological processing of the CO-X type fibers also resulted in the 
staining of the MAC-Ts’ nuclei (blue).  The micrographs taken on Day 1 reveal 
striations that were caused by razor blade sectioning, as shown in Figure 3.18.  
The sections stained on Day 7 disclose the 3-D structure of the fiber as well as 
the distribution and morphology of the cells (Figure 3.19).  Cells are located 
sporadically within the fiber wall.  Most of the cells remain in the rounded 
morphology.  After 14 days of culturing, the wall of the CO-X type fiber remained 
intact, as shown in Figure 3.20).  However, it appears that cells had not been 
encapsulated from the 9 o’clock to the 12 o’clock position in this particular inch of 
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fiber (Figure 3.20A).  Day 21 sectioning and staining reveals that the CO-X 
spinning trial did not encapsulate cells from the 9 o’clock to the 12 o’clock 
position (Figure 3.21).  Notice that sections of the fiber walls appear to be on 
these pictures reveal that the hollow fiber appears to be twisted (Figure 3.21A-C).  
Finger-like voids appear in the hollow fiber wall (Figure 3.21D).   
 
 
Day 1 – 100X 
Day 1 – 400X
Day 1 – 100X
 B 
 A 
 D 
 C 
Day 1 – 200X
Figure 3.18: Day 1 toluidine blue staining pictures of CO-X encapsulated MAC-
Ts.  Total magnifications are indicated.   
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Day 7 – 25X 
Day 7 – 100X
Day 7 – 100X
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Day 7 – 100X
Figure 3.19: Day 7 toluidine blue staining pictures of CO-X encapsulated MAC-
Ts.  Total magnifications are indicated.   
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Figure 3.20: Day 14 toluidine blue staining pictures of CO-X encapsulated MAC-
Ts.  Total magnifications are indicated.   
Day 14 – 25X 
Day 14 – 100X
Day 14 – 100X
 A  C 
 B  D 
Day 14 – 100X
 
   93
 
Figure 3.21: Day 21 toluidine blue staining pictures of CO-X encapsulated MAC-
Ts.  Total magnifications are indicated.   
 
3.2.7 Histomorphological analysis 
 
One-factor ANOVA tests were performed on the Y/X ratio (Figure 3.22) 
and cell area (Figure 3.23) data, which were followed by calculations of Fisher’s 
Least Significant Differences (LSDs) to compare the means of these two 
measurements from days 1, 7, 14, and 21 for each encapsulation method.  For 
the MI study, there was a significant difference in the Y/X ratios between Days 1 
and 21, and 14 and 21.  For the CO-X study, there was a significant difference in 
the Y/X ratio between days 1 and 7, and 1 and 21.  There was also a significant 
difference in the cell area between Days 1 and 21 and Days 14 and 21.  For the 
CO-X study, there was a significant difference in the cell area between Days 1 
Day 21 – 25X 
Day 21 – 100X
Day 21 – 100X
A 
B 
 C 
 D 
Day 21 – 100X
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and 7, and 7 and 14.  The p-values corresponding to the ANOVA tests employed 
for the Y/X ratios and cell area were 3.09E-12 and 3.92E-04 (n=20), respectively.   
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Figure 3.22: Box and whisker plot of the y to x ratio calculated as part of the 
histomorphological analysis of the MI and CO-X encapsulation methods over 21 
days (n=20).  Notice that the distribution of the Y/X ratio for the CO-X 
encapsulation method does not vary greatly over the duration of the study.           
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Figure 3.23: Box and whisker plot of the cell area calculated with the 
histomorphological analysis for the MI and CO-X encapsulation methods over 21 
days (n=20).  
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CHAPTER FOUR 
 
DISCUSSION 
 
 
4.1 Sodium alginate solution properties 
 
Sigma Aldrich and Fischer Scientific are the distributors of sodium 
alginates, which are manufactured targeting viscosity specifications rather than 
molecular weight or M/G ratio.  Therefore the manufacturer only provides 
molecular weight ranges and a typical value for the M/G ratio for each lot 
number.  The manufacturers do, however, provide values for the apparent 
viscosity of these alginates at 2 wt% and 25 °C.  On the other hand, the standard 
operating procedures and specifications used to measure the viscosity, e.g., 
shear rate, type of rheometry, solvent ionic strength, are not disclosed; all of 
these factors have been found to affect the measurement of viscosity 1,2.  These 
possible differences in testing methods may explain the large differences in our 
assessment of the viscosity profile and the literature values3-5 provided by the 
alginate distributors, as shown previously in Table 3.3.   
Despite these potential differences in methodology, the main goals in our 
viscosity investigation were achieved.  These goals were to estimate the viscosity 
for the three alginate types, determine the extent to which the apparent viscosity 
of alginate is affected by concentration and shear rate, and to establish an 
acceptable fiber spinning viscosity that would promote the fabrication of a hollow 
fiber.   
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Determining the properties of alginate using a cone and plate rheometer 
employs the use of shear force measurements.  Therefore, the accuracy of shear 
force dependent viscosity measurements is based on the expectation that once 
the cone is set in motion, the alginate will conform to its geometry.  However, 
alginate is a non-Newtonian, pseudo-plastic material and can be best 
categorized as a complex fluid because it exhibits a nonconforming, solid-like 
behavior.  Physical evidence that alginate is a non-Newtonian fluid is the 
development of the die swell (extrudate swell) phenomena as alginate emerges 
from the capillary tube of the fiber spinneret pack6. The solid-like viscosity 
behavior of alginate was also confirmed through preliminary studies, and the 
extent of the solid-like viscosity behavior was found to depend on concentration, 
as shown in Figures 4.1(A-B).   
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Figure 4.1A:  The schematic curves of the apparent viscosity versus shear rate 
for alginate, a complex fluid.  The apparent viscosity decreases linearly between 
0.1 – 35 sec-1.  The decrease in apparent viscosity in response to an increasing 
shear rate is known as shear thinning6,7.  
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Figure 4.1B:  The schematic curves of the apparent viscosity versus shear rate 
for alginate, a complex fluid.  For a “solid-like” complex fluid, the viscosity 
decreases with increasing shear rate, which is known as shear thinning6,7.  
 
One may hypothesize that the differences between the literature and 
measured apparent viscosity values may be due to the Weissenberg effect.  The 
Weissenberg effect occurs when non-Newtonian fluids (i.e sodium alginate 
powder and water solutions) do not flow outward, but climb up the shaft of the 
cone that induces the high shear rate8.  Therefore, it is important to examine how 
the Weissenberg effect affects viscosity measurements with a plate and cone 
rheometer in order to understand how the accuracy of the molecular weight 
measurements may be limited by the chosen method of measurement.   
Guion and Hood suggest that the difficulty of using rotational devices to 
measure viscosity is that the Weissenberg effect causes a material gap to form, 
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especially with “tacky” substances, that breaks the contact between the cone 
height and the alginate.  They also suggest that in order to compensate for the 
Weissenberg effect, this material gap must be repacked between time points, 
and that the Weissenberg effect can be minimized by adding enough alginate to 
form a layer above the top of the cone9.  Figure 3.4 is an illustration of the shear 
rate dependent shear stress of MV sodium alginate that was gathered during 
preliminary trials in which we were learning how to effectively use the rheometer.  
The slopes of the curves shown are equal to the apparent viscosity.  From 0 to 
100 s-1, the apparent viscosity of the 6 wt% curve is increasing, and then 
decreases to nearly 0 at 600 s-1.  For shear rates higher than 600 s-1, the 
viscosity is negative, which goes against Newton’s first law, which says that there 
will always be an inertial force, or a resistance to flow, that must be overcome for 
movement to take place.  There are no free flowing fluids.  The curves for 6-8 
wt% exhibit the Weissenburg effect, which causes a material gap to form and 
breaks the contact between the cone height and the alginate.  This phenomenon 
is commonly referred to as “slip.”  Our contention is that when we established the 
viscosity profile of the three alginates types, a sufficient amount of alginate was 
added to the testing plate, thereby minimizing the Weissenberg effect.   
Section 2.2.3 describes the methods that were employed to determine the 
intermediate behavior of the spinning solution preparation.  Although the viscosity 
depends on temperature, it was believed that the relationship between the 
different types of alginates at 100 s-1 would not vary greatly between the 
temperature range of 20 and 25 °C.  Also, it is important to note that both of 
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these temperatures have been used in the literature for characterization 
purposes.  In order to compare the apparent viscosities of the three types of 
sodium alginates, an average temperature of 22.5 °C was used.  It was 
determined that the dependence of the apparent viscosity on alginate 
concentration was the greatest at a shear rate of 100 s-1 when compared with 
shear rates of 1,000 and 10,000 s-1.  The shear rate is synonymous to the rate of 
polymer extrusion in the spinning process.  The shear rate was estimated to be 
125 s-1 by using a shear rate equation specified for Newtonian fluids10.  The 
approach was deemed appropriate because it was observed that a 6 wt% MV 
sodium alginate solution exhibits a Newtonian-like behavior above a shear rate of 
65 s-1, as shown in Figure 4.1B.  The Newtonian-like behavior is one in which 
changes in the shear rate have minimal affects on the apparent viscosity. 
Figure 3.5 shows that 6 wt% MV based blends have experienced a time-
dependent viscosity.  It is thought that the decrease in viscosity may be due to a 
flow-induced breakdown or alignment of the polymer chains6.   
Perhaps it is not mere coincidence that the apparent viscosity of 6 wt% 
MV decreases by 50 % after being autoclaved.  The mechanism that would 
describe such an occurrence is called degradation.  Degradation is different from 
dissolution.  Alginate dissolution occurs because there is a lower concentration of 
a particular crosslinking agent outside the alginate matrix than there is within the 
alginate matrix.  Dissolution in alginate can also occur because another 
molecule, such as lactic acid, binds the  crosslinking agents.  The ultimate result 
in dissolution is that the alginate monomers become water soluble.   
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In the literature, researchers have degraded alginate by using acid, 
enzymatic hydrolysis, and gamma irradiation techniques. When alginate is 
degraded, a double bond is formed at the C4 carbon of the alginate monomers, 
resulting in D-glucono-lactone molecules that contain ketone functional groups11.  
It is also known that autoclaving alginate induces depolymerization of the 
alginate chains12.  Among the effects of degradation are a decrease in viscosity 
and molecular weight, and darker hue.  The decrease in viscosity and molecular 
weight occur primarily because of main alginate chain scission, and the darker 
hue occurs because of the formation of the double bond, which changes the 
refractive index of the alginate chains13. 
We have observed that autoclaving alginate can cause a decrease in 
viscosity, as shown in Figure 3.5.  We have also noticed that autoclaving 
changes the color of the sodium alginate solution from light brown to dark brown.  
The color change and the decrease in viscosity are both clues that lead us to 
infer that we may have changed the chemistry of our alginate precursor solution 
when autoclaving.   
4.2 M/G block ratio 
  
The statistical analysis revealed that there was a significant difference 
between the average %G block values calculated from Methods 1 and 2 and the 
average %G block values calculated using Method 3.  One major caveat in 
determining the M/G block ratio and the %G block was the limitation of literature 
values for the alginate types employed in this study.  In fact, the linear 
regressions employed in Methods 1 and 2 were fabricated using data from a 
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variety of brown seaweed species that included but were not limited to the brown 
seaweed species of macrocystis pyrifera.  Method 3, however, was a more 
conceptual method that was based on characteristic guluronic and mannuronic 
acid FTIR-ATR peaks14.  Nevertheless, the analysis was conducted for a sodium 
alginate that stemmed from the laminaria hyperborea species of sodium alginate.  
According to Smidrod and Brown, alginates derived from the macrocystis pyrifera 
species of brown seaweed have a M/G ratio and %G block in the range of 1.02-
1.52 and 39-50 %, respectively15.   
Prior to the study, two pieces of information were given that pertained to 
the M/G block ratio and %G block characterization.  It was known that the LV and 
MV alginate types from Sigma were from the Macrocystis pyrifera source of 
brown seaweed.  Second, according to Acros Organics technical support 
representatives, the %G block contained in the AO alginate type was between 
65-75 %3, which suggested that either the alginate originated from the 
Macrocystis pyrifera source of brown seaweed and was chemically modified to 
change the conformation of its M block residues to G block residues, or the 
alginate originated from a source that typically has a higher %G block associated 
with its polymer chains.  One example of the latter is laminaria hyperborea, which 
has a range of %G block between 44-70 % depending on whether the alginic 
acid is removed from the fronds or stipes of the brown seaweed plant16.  The 
three types of alginates are from the Macrocystis pyrifera source of brown 
seaweed; and since it is likely that the methods that used circular dichroism 
spectrophotometry were dependent on the concentration and the ionic strength 
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of the solvent, the FTIR-ATR technique remains as the method of choice for 
determining the %G block for alginates.  
4.3 Cell Response 
4.3.1 Lactic acid production and glucose consumption 
 
It was evident that lactic acid was produced and glucose was consumed 
by MAC-Ts under the MI and CO-X encapsulation methods (Figures 3.8 to 3.11).  
It is important to note that Figure 3.8 accumulates the glucose consumed by the 
encapsulated MAC-Ts. As shown in Figure 3.7 and 3.11, the distribution of the 
values recorded are heavily skewed to the right. When plotting the mean values 
plus or minus the standard deviation of all the samples collected on a particular 
day, the skew results in standard deviation bars that are less than zero.  
Therefore, the occurrence of these deviation bars that include negative values 
are not indicative of negatively measured values, but of a distribution that was 
heavily skewed to the right.   
    One can observe lag times in the MAC-Ts lactic acid production of one 
and five days, respectively.  Why do these lag times occur? Can and should 
these lag times be minimized?  Do the lag times exist only within the constraints 
of this experiment or do the lag times occur for all culture studies?   
Relative to the other days that the cells were in culture, the occurrence of 
these lag times in the production of lactic acid and consumption of glucose 
suggest that the cells were not as metabolically active.  One rationale for the lag 
time is that the cells were becoming acclimated to their encapsulation 
environment and that they were methodically leaving a state of inactivity after 
being exposed to nitrogen gas, sub-physiological temperatures, and a high 
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concentration of CaCl2 solution.  Statistically speaking, if we increased the 
number of fiber segments analyzed or the fibers were more porous over a 
greater range of the fiber length, would the results indicate that the lag time 
phenomenon does not exist?  Material scientists may pose the question of 
whether there are differences in the diffusion/transport capabilities of the two 
fiber types.  A shorter lag time may suggest that the fiber may have larger pore 
sizes (less selectivity) or a higher degree of pore connectivity.  On the other 
hand, a longer lag time suggests that the fiber may have low lactic acid diffusion 
rates to the culture medium because of smaller pore sizes (higher selectivity) and 
less pore connectivity. The MI encapsulation method was a bi-component fiber, 
comprised of a 0.74 wt% low viscosity alginate base in the lumen and 6 wt% 
medium viscosity in the annular.  The differences in diffusion properties may also 
suggest that the CO-X is advantageous because it naturally limits the diffusion of 
molecules.  The dilute concentration of low viscosity used as the cell suspension 
matrix in the manual injection method had a lower density than the 
10:1::autoclaved 6 wt% MV alginate:DMEM solution that was used to 
encapsulated the MAC-Ts under the CO-X method.  It is intuitive that a lower 
density alginate has less inertial forces, prohibiting its movement with respect to 
a higher density alginate.  Therefore, a lower density alginate has a lower matrix 
modulus and shear force of extrusion.  A lower density alginate imposes less 
shear forces onto the cell membranes during co-extrusion or manual injection, 
since a smaller shear force is required to extrude or inject the cells, respectively.  
Frangos and coworkers provided a review on the effect of shear stress on cell 
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metabolism17-19.  They found that shear stress can expedite metabolite 
production, increase the strength of attachment, and promote the viability of 
anchorage-dependent mammalian cells.  They also propose that shear stress 
acts as an external stimuli to the cell cytoskeleton, causing signal transduction 
across the cell plasma membrane that stimulates cell metabolism.  
 Initially, a rat aorta fibroblast cell line was used as an adhesion dependent 
model to access the feasibility of cellular incorporation.  However, we were 
unable to qualitatively distinguish these cells from the fiber matrix without 
employing destructive methods.  Fortunately, a hardy GFP labeled MAC-T cell 
line was readily available, and the expression of GFP from the MAC-Ts offered a 
non-destructive alternative to making qualitative assessments of the MAC-Ts’ 
viability, metabolism of glucose, and location within lumen or wall of the fiber.  It 
is highly likely that these metabolic activity results are dependent upon cell type. 
4.3.2 Alamar Blue 
There was no significant differences in the alamar Blue reduction between 
Days 1 and 21 for either encapsulation type.  One may hypothesize that alamar 
Blue reduction is not an effective method to determine the cellular respiration / 
glucose metabolism of encapsulation cells because the method that was 
employed in this study was based on a protocol developed within our lab to study 
the cellular respiration of cells seeded on the surface of scaffolds.  Furthermore, 
the C/A ratio remained close to a value of 1.  Nevertheless, a low C/A ratio was 
expected.  In fact, it is our contention that this study should not be excluded; 
because, during preliminary studies, three 1-inch co-extrusion type fiber 
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segments were placed in a single well of a 6-well plate, and it was determined 
that increasing the cell number increased the validity of the alamarBlue study.  
Specifically, it was determined that the success of the alamarBlue assay is 
dependent upon controlling and maintaining a threshold cell density of 1.2 X106 
cells/1-inch fiber.  In addition to improving the effectiveness of the cell counting 
method, an attempt was made to reach the threshold cell density by increasing 
the targeted cell seeding density from 1.8 X 106 to 3.0 X 106 cells/mL (alginate + 
DMEM).  These attempts to reach the threshold cell density resulted in an 
average cell count of approximately 5.7 and 3.1 X 105 cells/1-inch fiber for the MI 
and CO-X encapsulation methods on Day 1, respectively.  These cell counts 
reveal an opportunity to overcome equipment design limitations by using a higher 
target cell density of 0.65 – 1.2 X 107 cells/mL (alginate + DMEM).  Perhaps, a 
more suitable encapsulation material will require fewer cells to yield the desired 
alamar Blue reduction response that was given by 1.2 X106 encapsulated MAC-
Ts. 
4.3.3 Cell number 
Two issues regarding the cell number must be addressed.  First, the 
difference between the targeted cell seeding density and the actual cell seeding 
density must be minimized.  The actual cell seeding density was less than the 
targeted cell seeding density in the co-extrusion method.  The difference in 
seeding cell density can be attributed to the lack of an even cell distribution within 
the polymer chamber.  Although the alginate-DMEM/cell mixture was well mixed 
when the chamber was loaded, an uneven distribution of cells may have been 
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promoted due to axial mixing.  It was thought that that partially filling the polymer 
chamber with a green colored acellular alginate solution prior to loading the 
cellular alginate-DMEM mixture would enable an operator to establish the hollow 
fiber spinning conditions to spinning cellular fibers.  However, it was determined 
that axial mixing occurs, because the initial and final segments of the hollow 
fibers contained traces of green dye and were cellular.  The axial mixing can be 
attributed to the nitrogen pressure spike that occurs prior to spinning.  The 
pressure spike effect is a design limitation.  One may hypothesize that the 
pressure spike can be minimized by maintaining the extrusion lever in the ON 
position (vertical) after polymer loading, so that the alginate/DMEM cell 
suspension will be extruded initially by gravitational forces, and once the nitrogen 
flow begins, the extrusion will occur and the axial mixing will be minimized.   
The second issue that must be addressed regarding the cell number is the 
high variability on Day 21 of the cell number measurements.   It is important to 
reemphasize the method by which the cells were counted, namely, the 
dissolution of the alginate fiber in order to release the encapsulated cells.  The 
cell population of a fiber could not be measured on different days using this 
destructive method.  Therefore, the variability that occurs shows the lack of 
consistency in the population of cells within each fiber.  For the co-extrusion 
method, an even distribution of cells was initially assumed and 6ft of cellular 
hollow fiber was spun, cut into 1-inch segments and cultured and analyzed in the 
same order in which they were spun.  The first 12 fiber segments were used in 
the cell response analysis during Days 1-7, the next 12 fiber segments were 
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used during Days 8-14, and a third set of fiber segments were analyzed during 
Days 15-21.  Therefore the high variability may be explained as the cell seeding 
density increasing along the length of fiber.  The high variability for the MI 
method on Day 21 may be explained by limitations in the manual extrusion 
method.  A 3mL syringe was used to add a suspended cell solution to the lumen 
of hollow fibers, and the ends of these filled fibers were gelled.  The syringe was 
refilled from a stock solution of cells after all of the solution in the syringe had 
been added to fibers.  It is possible that while the solution in the syringe was 
being added to the hollow fibers, the cells in the stock solution may have 
aggregated.  If true, then the extent of the cell aggregation may have increased 
as more fibers were filled.  This hypothesize would indicate that the syringe that 
was used to fill the fibers that were analyzed during Days 15-21 contained either 
a higher actual cell seeding density than the targeted cell seeding density, an 
even distribution of the cells within the suspended cell solution in the syringe, or 
possibly a combination of these two occurrences.  Cell aggregation could be 
minimized and an even distribution of cells could have been promoted through 
the agitation of the stock solution of suspended cells20.     
4.3.4 Histology  
Is it a coincidence that there are very few cell aggregates and that most of 
the cells are round (Fiber 3.18)?  We may also see an effect from using a higher 
concentration of alginate.  Perhaps less cell aggregates develop when 
encapsulation matrix consists of a higher concentration of sodium alginate.  It 
can be hypothesized that MAC-Ts conform to the cobblestone morphology when 
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multiple cell-cell junctions are available and that cells have more mobility in less 
concentrated alginate gels. 
Figure 3.19A suggests that the distribution of cells into the hollow fiber can 
vary during the duration of the process.  Is there a coincidence that the fiber wall 
does not contain holes?  There may be a link between MAC-T lactic acid 
production and the increased rate of fiber decalcification and alginate 
dissolution21.  If lactic acid production contributes to fiber decalcification, then an 
expedited rate of alginate dissolution may explain the gaps shown in Figure 3.20.  
Clinicians use hollow fibers containing membrane voids in selective 
permeability applications such as membrane oxygenation and hemodialysis22.  
The void structure of a fiber membrane depends on processing conditions, such 
as how the exchange rate of the solvent/coagulant during the wet phase 
inversion process is controlled23.  These processing conditions can be used to 
produce sponge, cylinder, and finger voids.  Finger voids can normally be formed 
during the phase inversion process, when demixing occurs between two 
immiscible liquids (i.e. polymer solvent and water) so that the membrane consists 
of the porous sheath that covers an internal finger-type structure. 
However, in our dry/wet spinning process, our polymer solvent (distilled water) is 
miscible with our coagulant solution (aqueous calcium chloride) and yields fibers 
with a five layer morphology (Figure 4.2).  We hypothesize that the annular gap 
forms because as the hollow fiber membrane is crosslinked from the periphery 
and lumen side of the hollow fiber, it is pulled in the direction of the coagulant.  
The annular gap is not formed when glycerol is added to the alginate solution.  
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Perhaps, the rate and extent of alginate crosslinking is impeded by glycerol’s 
hydroxyl (-OH) functional groups.  
The lactic acid produced by the MAC-Ts, slowly decalcified the fiber wall.  
A two-way influx of medium into these interstitial sites of decalcified alginate 
further promotes dissolution and finger-type void formation, as shown in Figure 
3.19D.  The formation of these voids creates porous hollow alginate fibers.  If the 
formation of these finger voids could be controlled could be advantageous for 
use in selective permeability applications.   
 
 
 
Figure 4.2: The five layer morphology consists of thin sheaths of highly 
crosslinked alginate on the periphery and the interior of the lumen.  A spongy-like 
alginate support matrix which is concentrically divided by an annular gap is 
contained within these thin sheaths.   
 
A modified GMA embedding technique was employed to minimize the 
effect of histological processing on the hollow fiber geometry for Day 1 for the 
CO-X type hollow fibers, since the gelation technique employed on the internal 
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cell suspension of the MI type hollow fibers significantly reduced the volume of 
their cell suspensions.  The cell suspension volume reduction made the MI 
hollow fiber susceptible to concaving inward during the dehydration and 
polymerization steps of the 90 minute GMA embedding process.   
Attention must be paid to the fixation method used to preserve the 
morphology of the MAC-Ts, and to the sectioning method that was employed to 
prepare the sections for staining.  It was observed that if exposure time of the 
hollow fiber to 10% NBF extended beyond 2 minutes, the fiber would begin to 
swell.  The formalin was diluted in PBS, and it is probable that the swelling 
occurred from contact with the PBS and not with the formalin itself.  Perhaps a 
three step process involving cell fixation, re-gelation, and dehydration could be 
used to preserve both the MAC-T and fiber morphologies.  Possible options for 
the fixation would be to increase the concentration of the NBF or use a fixative 
that is more potent than NBF, such as gluteraldehyde, in order to decrease 
swelling effect and exposure time24.  A review of fixative diffusion rates has been 
thoroughly discussed in the literature and suggests that a fixation time of 2 
minutes using 10% NBF is not adequate25.   
4.4 Limitations of the current design of the hollow fiber spinning   
technology   
 
The experiment also reveals several limitations of the current design of the 
hollow fiber spinning technology for its use in cell encapsulation.  The current 
design lacks the temperature control, chamber gas, and mixing devices that 
would be desired to maintain physiological conditions (i.e. 5 %CO2 and 37 °C) 
and an even distribution of cells within a polymer matrix in the polymer chamber.  
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The cells are exposed to lower temperatures and a high nitrogenous environment 
during the co-extrusion encapsulation method, which may be the key contributing 
factor to the lag time, or period of adjustment observed in the MAC-Ts’ lactic acid 
production and glucose consumption.  Lower temperatures cause a decrease in 
the cell metabolic activity.  Exposure to high nitrogenous environments may 
induce hypoxia, which has been known to induce a quiescent state in many cell 
types26.  The variations in the cell count and assessment of the glucose 
metabolism studies may be attributed to the lack of an even distribution of cells 
within the polymer chamber, which directly affects the distribution of cells along 
the length of the extruded fiber.  There was also a high variation in the cell count 
on Day 21 for both extrusion methods.   
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CHAPTER FIVE 
 
CONCLUSIONS AND RECOMMENDATIONS 
 
 
5.1 Conclusions 
5.1.1 Material characterization 
 
Based on our findings, we can conclude that the viscosity profiles of the 
three alginate types differ, and that the type of alginate selected for future 
encapsulation studies will depend upon the targeted clinical application.  Of the 
three alginate types, the LV sodium alginate has the lowest molecular weight, a 
requirement for renal clearance, and would therefore be the ideal candidate for 
short-term in vivo applications.  We can also conclude that there is no difference 
in the G block % among the three alginate types.   
5.1.2 Cell response 
Based on our findings, our novel in-house textile hollow fiber spinning 
process can be used to encapsulate cells in MV and LV alginate-based solutions.  
Over the duration of 21 days, MAC-Ts encapsulated under the CO-X method 
produced less lactic acid and consumed less glucose.  Based on the staining 
techniques employed and histomorphological analysis performed, we can 
conclude that the formation of cell clusters were inhibited when the cells were 
encapsulated in a 6 wt% MV based alginate solution using the CO-X 
encapsulation method.  However, cell spreading occurred more readily in the MI 
type fibers than in the CO-X type fibers because of a less concentrated alginate 
matrix.  Second, we can conclude that by Day 21, the cell area of MAC-Ts that 
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were encapsulated using the MI method exhibited larger cell areas than MAC-Ts 
encapsulated by using the CO-X method.  Third, we can conclude that the 
production of lactic acid contributed to alginate dissolution.   
5.2 Recommendations 
Future work should address four initiatives.  The first initiative should 
involve increased characterization of the sodium alginate and study of the effect 
of the measured properties on the MAC-Ts’ viability and metabolic activity.  The 
arrangement of the M and G blocks for each type of alginate should be 
determined to correlate conformation with viscosity.  In addition, the influence of 
each alginate type’s molecular weight on the cell viability and metabolism should 
be studied.  
Second, the physical properties of the hollow fiber and how these 
properties change over time in vitro should be characterized.  Currently, the 
tensile strength of a hollow fiber is difficult to measure because a gap exists in 
the wall of the fiber.  A method to measure the tensile properties of the alginate 
hollow fibers should be devised.  Atomic force microscopy (AFM) should be used 
to study how different alginate molecular weights, coagulation concentrations, 
and culturing methods influence the fibers’ surface topology on a nanometer 
scale.  Perhaps AFM should be used as a method of determining membrane 
porosity.  Improving the characterization of the hollow fiber should include 
improving the histological methods detailed in this thesis.  Namely, a more 
adequate fixation method must be devised that will elucidate the in vitro cell and 
fiber morphology through the preservation of cells and hollow fiber.   
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Third, future work should include studying the effects of proposed changes 
in the hollow fiber spinning technology on cell viability, metabolism, distribution, 
and fiber spinnability.  One proposed change is to replace the nitrogen gas, used 
in the spinning process, with oxygen.  The effect of oxygen on the cell’s 
susceptibility to shock should be investigated because it has been proposed that 
nitrogen may be causing a delay in the cell cycle.  Normally, mechanical stimuli 
cause the compression of the cell’s cytoskeleton, which transmits signals to the 
cell nucleus.  However, this effect may be inhibited in cells that experience 
hypoxia, which is promoted in a highly nitrogenous environment.  Therefore, the 
effect of oxygen on alginate gelling should be determined.  Since alginate is 
ionotropic and oxygen is high reactive and negatively charged, alginate exposure 
to oxygen may have some inhibitory effects on the binding of calcium to the 
alginate carboxylic acid group’s anion.  Another proposed change is to maintain 
physiological temperature conditions (37°C).  Therefore, the effect of increasing 
the temperature of the coagulation fluid and the alginate spinning solution to 
37°C on fiber spinnability and cell viability should be investigated.  Increasing the 
bath temperature would increase the rate of gelation, which may promote a 
larger mechanical stress on the cells.  One of the limitations of the current 
spinning system is that the CO-X extrusion method does not maintain an even 
distribution of cells in the spinning matrix.  Thus, it would be intuitive to determine 
the optimal operating conditions for a baffle/mixer system within the polymer 
chamber that will maintain an even cell distribution with minimal cell detriment.  
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 Fourth, in order to validate the feasibility of using the spinning apparatus 
for encapsulating cells and define the limitations of the purposed encapsulation 
methods, other cell lines, including an adhesion dependent human cell line, 
should be encapsulated and undergo viability and metabolic activity evaluations. 
 
